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Populärvetenskaplig sammanfattning 
 
Blodkärl finns i hela kroppen. De syns för det mesta som turkosa strängar under huden 
när vi ser efter. De är oerhört viktiga för vår överlevnad och bildandet av nya blodkärl 
är som allra viktigast när våra sår läker, under menstruation och graviditet samt 
självklart under fosterutvecklingen i mammans mage. Lagom är bäst tycker kroppen 
och därför ställer överdriven eller otillräcklig blodtillförsel till med problem och 
sjukdom. I den här avhandlingen har jag fokuserat på sjukdomen cancer.  
 
Tumörer kan inte överleva och växa bortom ett knappnålshuvuds storlek utan syre och 
näring. Därför åker de snålskjuts på kroppens eget maskineri och lockar till sig blodkärl. 
I och med detta kan tumören inte bara växa utan har också införskaffat ett sätt att sprida 
sig på, metastasera. Sammantaget är detta anledningen till att hög blodkärlsnärvaro i 
tumörer inte är bra när man talar om patienters prognos.  
 
Blodkärl består av speciella celler, så kallade endotelceller. Nya blodkärl kan bildas 
(förgrenas) från ett befintligt kärl genom att endotelcellerna, likt en ny kvist på en gren, 
börjar växa, dela sig och röra sig från det befintliga blodkärlet (grenen) mot t.ex. 
tumören. Detta kallas angiogenes. Det finns andra sätt för blodkärl att bildas på, men 
detta är det i särklass vanligaste sättet som det sker på i en tumör.  
 
Jag har studerat proteinet Angiomotin, ett protein som vi har visat är viktigt för 
endotelcellernas rörelse. Man har visat att Angiomotin binder till speciella, 
kolesterolrika fettmolekyler, till proteiner viktiga för celldelning och till så kallade 
polaritetsproteiner. De sistnämnda ger cellen en känsla för vad som är fram och bak när 
den ska röra sig. När celler tappar den förmågan blir de antingen stillasittande eller rör 
sig helt slumpartat åt olika håll.  
 
Forskargruppen jag tillhört har visat att vaccination mot Angiomotin både skyddar möss 
mot tumörutveckling och att befintliga tumörer hämmas i sin tillväxt. En potentiell 
terapeutisk antikropp mot Angiomotin som vi, tillsammans med läkemedelsföretaget 
BioInvent, tagit fram har visat på kraftigt minskad kärlinväxt i tumörer och 
tumörsimulerande material. Mer arbete med att utveckla antikroppen kommer dock att 
behövas för att ge den en tillräckligt bra livslängd i kroppen för att vara praktiskt 
användbar. I ett hitintills opublicerat arbete har jag bidragit till att försöka öka 
livslängden på antikroppen och har varit med när vi gjort försök att kunna använda den 
för diagnostiska ändamål.  
 
I den här avhandlingen visar jag hur Angiomotin binder till sina olika partners och 
varför detta påverkar endotelcellernas rörelse. Påståendet att Angiomotin ska vara ett 
mål att attackera för potentiella läkemedel får ytterligare tyngd i och med de fynd som 
gjorts. Vi har till exempel sett att tillväxten av neurofibromatos, en sjukdom där tumörer 
växer längs med hjärnans och ryggmärgens nerver, till stor del är beroende av 
Angiomotin. Jag hoppas att mitt arbete och det som kommer ske efter att jag lämnat 
denna forskargrupp bidrar till nya behandlingssätt mot cancer.  
 
MAKING ENDOTHELIAL CELLS MOVE – A STUDY OF ANGIOMOTIN AND BINDING PARTNERS 
 
 
 
Abstract 
 
Angiogenesis is a process crucial for tumor growth and metastasis formation and 
encompasses the control of endothelial directional migration, anastomosis and lumen 
formation. We have previously shown that Angiomotin (Amot), a membrane-associated 
scaffold protein, plays an essential role in controlling endothelial cell migration and 
cell shape. Amot is critical for normal development as more than 75% of amot deficient 
mouse embryos die in utero due to vascular defects. 
     In this thesis, the vascular system of the mice that survive gestation are studied. 
These mice are apparently normal in regards of body weight, kidney function and 
reproduction. Further, the vascular system did not exhibit any changes in perfusion or 
vascular density. However, the growth of Lewis Lung Carcinoma tumor xenograft was 
significantly impaired in amot deficient mice as compared to sibling wt mice. Analysis 
of the tumor vasculature revealed a marked change in vessel morphology and 
decreased vascular density and perfusion. These data argue that Amot, besides its role 
in development, plays a critical role in pathological angiogenesis. Gene expression 
analysis shows that the loss of amot expression leads to indirect effects, which activates 
NF-κB regulated genes and results in an inflammatory phenotype in vitro and in vivo.  
     As the thesis title implies, the function of Amot in endothelial cell migration has 
been investigated by identifying and studying its binding partners and their functions. 
The polarity proteins Patj and Mupp1 (plus Pals1) are presented as binding partners to 
the Amot PDZ-binding motif. This is of interest since establishing cell polarity is a key 
step in directional endothelial migration. Migration also depends on correct actin 
polymerization, driven by Rho GTPases. We show that Amot is essential for the 
localization of RhoA activity at the leading edge of a migrating cell and that the Rho 
GEF (activator of RhoA) Syx1 also associates to Patj/Mupp1. Finally, we show that the 
interaction of the PDZ-binding motif to Patj/Mupp1/Syx1 is essential for vessel 
migration in developing zebrafish embryos.  
     Furthermore, tight junction-associated tumor suppressor Merlin (nf2) is identified as 
a binder to the Amot coiled-coil domain. Rich1, a negative regulator of Rac1 (also a 
RhoGTPase), has been shown to bind to Amot through the same domain. We show that 
Amot regulates Rac1 activity and subsequent MAPK pathway activation through Merlin 
and Rich1 and that Merlin and Rich1 compete for the same binding site on Amot, 
resulting in Rac1 regulation. We hypothesize that Rich1 is inhibited by its binding to 
Amot, leaving Rac1 in its active state, able to polymerize actin. Upon binding to 
Merlin, Amot releases Rich1 and Rac1 is inhibited. Finally, we show that Schwann cell 
tumors, caused by loss of nf2 expression, exhibit a decreased growth rate upon loss of 
amot expression, leading to prolonged mouse survival. This further emphasizes the 
potential for Amot as a drug target and indicates that anti-Amot therapy could be used 
to treat Schwanoma patients. 
     Amot localizes to the lamellipodia of migrating cells, a region of the cell membrane 
with specific lipid composition. The Amot coiled-coil domain has been shown to be a 
conserved lipid-binding domain. I propose a model where migratory cues trigger the 
change in lipid composition of the cell membrane, concentrating lipids to which Amot 
binds to the lamellipodia. Amot brings with it the complex of Patj/Mupp1:Syx1, 
localizing RhoA activity and thus actin polymerization at the leading edge. 
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1. The Hallmarks of Cancer and Cancer Microenvironment 
 
Cancer is a heterogeneous disease that comes in many shapes, sizes, origins, 
causes, compositions, behaviors and most importantly, outcomes. Unlike e.g. 
chicken pox, cancer is not a single disease; it is the collective name for illnesses 
that share some common characteristics, the main one being continuous, abnormal 
growth of cells. In turn, ‘breast cancer’ is a collective term for tumors originating 
from or growing in breast tissue, sharing some traits but still differing immensely 
amongst themselves.  
 
Tumors start out as benign and may progress into malignancy, meaning that it has 
become more aggressive, is growing outside its original compartment and is 
spreading. This change, called tumor progression, occurs as the tumor cells 
undergo dynamic genetic changes, leading to the selection and clonal expansion of 
those cells that have gained advantageous characteristics. In 2000, Douglas 
Hanahan and Robert Weinberg came up with the term ‘The Hallmarks of Cancer’ 
Figure 1 [1, 2]. They state that all the tricks we see cancer cells (of any kind) 
perform boil down to eight essential alterations in cell physiology:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The Hallmarks of Cancer - The Next Generation. Modified 
from Hanahan & Weinberg. 2011. Cell.	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• Self-sufficiency in growth signals 
• Insensitivity to growth-inhibitory (antigrowth) signals 
• Evasion of programmed cell death (apoptosis) 
• Limitless replicative potential 
• Sustained angiogenesis 
• Tissue invasion and metastasis 
• Evading immune destruction 
• Deregulating cellular energetics 
 
‘Genome instability & mutations’ and ‘Tumor-promoting inflammation’, in Figure 
1, are not Hallmarks per se, but are events that drive tumor progression and 
facilitate acquisition of the Hallmarks. 
 
During the last decades, major research efforts have focused on understanding the 
mechanisms underlying cancer development. With time the way of viewing cancer 
has changed, which is clearly shown in Figure 2. Instead of studying the mere 
tumor cells, the tumor is now considered to be as intricate as any organ, with all 
the added complexity of interacting cell types that comes with it [3-8]. I will focus 
the remainder of this section on the other cell types within and surrounding the 
tumor, the so-called tumor microenvironment, and how they contribute to the ever-
mounting complexity of cancer.  
 
 
 
 
1.1 Fibroblasts 
 
Fibroblasts are a kind of cell found most abundantly in connective tissue. 
They produce the Extracellular Matrix (ECM), the fundamental framework 
that all cells utilize for adhesion and migration. They also modulate the 
Figure 2. The Tumor Microenvironment. Modified from Hanahan & Weinberg 2011, Cell. 	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surrounding cells by secreting growth factors and cytokines [9]. Fibroblasts 
are heterogenous in morphology, changing appearance depending on their 
localization [10]. 
 
Cancer associated fibroblasts (CAFs) is a term that encompasses a very 
heterogenic group of fibroblasts, sharing their morphological appearance 
as fibroblasts, their localization in the tumor stroma and expression of a 
few surface markers: α-smooth muscle actin (α-SMA), platelet-derived 
growth factor (PDGF) receptors and Fibroblast specific protein (FSP)-1) 
[11]. Some claim CAFs to originate from bone-marrow progenitor cells, 
others say they are local tissue-derived fibroblasts and there are also 
reports of transdifferentiating epithelial cells [12-15]. 
 
Studies on CAFs have mostly been conducted by co-injecting them 
together with tumor cells into mice and subsequent observation of the 
altered characteristics of the tumor cells. The collective conclusion is that 
CAFs have a cancer-initiating capacity, stimulate tumor cell proliferation 
and stimulate angiogenesis. This is done by providing the ECM for the 
endothelial cells to migrate and by expressing the essential growth factors 
needed for the survival and stimulated migration of vascular endothelial 
cells [11]. The net effect is that CAFs facilitate the initiation, growth, 
invasion and metastasis of tumors [9, 16]. Moreover, it has been shown 
that CAFs mediate drug resistance to therapies such as anti-angiogenic 
drugs and tyrosine kinase inhibitors [11] [17]. Therefore, the notion of 
using CAF gene signatures both for prognosis and response-prediction to 
therapy is being studied, with promising results [11, 18]. 
 
1.2 Immune Cells 
 
The inflammatory system is a complex and fascinating system. Not only 
can it rid us of diseases, adapt and learn it can cause havoc in the shape of 
allergies, autoimmune diseases and cancer. The latter happening as 
chronic inflammation drives tumor progression into a more aggressive 
disease [19, 20]. As a token of their omnipresence in our lives tumor-
infiltrating immune cells are a frequent finding when studying patient 
tumor biopsies. However, unlike the presence of blood vessels, which is 
unanimously considered poor for patient prognosis immune cells have 
conflicting functions meaning that their general presence is ambiguous 
[20-22].  
 
There is an ever-growing list of tumor-promoting molecules secreted by 
inflammatory cells. On the list are growth factors such as Epidermal 
Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF) and basic 
Fibroblast Growth Factor (bFGF), chemokines, cytokines and also pro-
angiogenic and pro-invasive factors such as Matrix Metalloproteinase 
(MMP)-9 and proteases [23, 24]. As a result, infiltrating immune cells may 
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promote tumor proliferation, spur angiogenesis and facilitate 
invasiveness/metastasis.  
 
Tumors try to evade the anti-tumorigenic part of the immune system, like 
the Cytotoxic T-Lymphocytes (CTLs) e.g. by downregulating receptors that 
may trigger immune responses, like Major Histocompatibility Complex 
(MHC) class I [25, 26]. They secrete anti-inflammatory factors to throw the 
attacking immune cells off their scent and to recruit tumor-promoting 
immune cells. It is a delicate balance. While the presence of Natural Killer 
(NK) cells and CTLs indicates anti-tumorigenic activity and thus is 
beneficial for patients, these cells may be rendered anergic. The 
combination of factors secreted by the tumor and the cells recruited, can 
result in an unfavorable milieu. Bone-marrow-derived myeloid cells 
differentiate into several cell types in response to tumor-secreted factors. 
They become Tumor Associated Macrophages (TAMs), Myeloid Derived 
Suppressor Cells (MDSCs) and Tolerogenic Dendritic Cells (DCs). The latter 
stimulates the differentiation of bone-marrow-derived progenitor cells into 
Regulatory T Cells (Tregs). Just as they would in a healthy individual Tregs 
suppresses immune response and maintains the tolerance to self-antigens. 
This means the double presence of CTLs and Tregs results in no killing of 
tumor cells [22]. To add insult to injury both MDSCs and TAMs secrete e.g. 
Arginase 1 (Arg1), digesting L-arginin needed by the CTLs and as a result 
causing anergy and a lack of tumor killing [27]. As a result, knowledge of 
both environment and cell types present is needed in order to make an 
assessment if the tumor is being helped or fought by the immune system in 
a given tumor.  
 
 
1.3 Pericytes 
 
Charles Rouget unknowingly described the first pericytes as far back in 
time as the late 19th century. He observed cells with distinct finger-like 
cytoplasmic projections that wrapped themselves around capillaries [28-
30]. Today, the envelopment of capillaries still is the common trait of all 
pericytes (see Figure 3). They form a continuous sheath around endothelial 
tubes, with smooth muscle cells replacing them on larger vessels. The 
number of pericytes per vessel varies depending on localization in the 
body and the characteristics of the vessel to envelope [31]. 
 
Pericytes are related to smooth muscle cells and differ in morphology 
depending on their origin or their microenvironment, i.e. the vascular bed 
and their position along the arterio-venous axis. [32] [31] [33]. Pericytes 
stem from different origins: proliferative expansion of pre-existing local 
pericyte-pools (longditudinal recruitment) [34] [35, 36] and differentiation 
from mesenchymal cells (fibroblasts) [37]. In the Central Nervous System 
(CNS) pericytes originate from both mesoderm-derived mesenchymal stem 
cells and neuroectoderm-derived neural crest cells, depending on the 
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location within the developing cerebrovascular tree [38]. Mesoderm-
derived bone marrow progenitor cells have also been shown to contribute 
to the CNS pericyte population after ischemia [39, 40]. This differs from 
endothelial cells, which are thought to be of uniform origin, with the 
exception of tumor endothelial cells.   
 
 
 
 
 
In turn, pericytes may differentiate further into smooth muscle cells and 
macrophages. In a kind of limbo between the cell types, pericytes may 
acquire macrophage-like phagocytotic qualities that enable them to clear 
toxic substances and byproducts [38, 41]. Again, this feature is most 
important and mostly studied, in the CNS.  
 
Despite the heterogeneity pan-pericyte markers can be found. Pericytes of 
different kinds express non-muscle myosin, tropomyosin desmin, nestin, 
platelet-derived growth factor receptor β (PDGFR-β), aminopeptidase A, 
aminopeptidase N (CD13), sulfatide, α-smooth muscle actin (ACTA2/α -
SMA) and nerve/glial antigen 2 proteoglycan (NG2) [42]. In quiescent 
tissue the common denominator for pericytes is that they all express 
PDGFR-β, NG2 and Desmin. The expression of α-SMA appears to differ 
depending on what pericyte-type is observed, where it resides and which 
state it is in. This has given rise to a debate as to whether or not α-SMA is a 
pan-pericyte marker [38]. However, in tumor vasculature α-SMA is 
expressed.  
 
As a relative to smooth muscle cells pericytes have contractile capabilities, 
making it possible to constrict blood vessels, regulating blood flow, in 
Figure 3. Smooth muscle cell coverage of arterioles and pericyte 
coverage of capillaries. Modified from Hamilton et al. 2010. Front 
Neurogenetics. 
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response to neuronal signals. This is most essential for the functionality of 
the Blood-Brain Barrier (BBB), where the constriction of the cerebral 
capillaries allows/disallows access for larger proteins and particles to the 
brain. As a consequence of this necessity CNS vasculature has significantly 
higher pericyte coverage than do peripheral tissues [31, 38]. 
 
Pericytes are interconnected with endothelial cells both mechanically 
through their shared, commonly secreted, basement membrane and 
through shared ions and molecules via gap junctions [43]. These bi-
directional junctions enable the cells to communicate and influence each 
other’s behavior. The Endothelial Cells (ECs) secrete soluble factors such as 
PDGF and basic Fibroblast Growth Factor (bFGF) that promote pericyte 
proliferation and migration. Studies on mouse genetic models show that 
the recruitment of pericytes to normal and tumor vessels are dependent on 
the PDGFR-β signaling pathway [35].  
 
In turn, the pericytes secrete multiple factors that affect the ECs. 
Angiopoietin (Ang)-1 is secreted by pericytes and it binds to Tyrosine 
kinase with immunoglobulin-like and EGF-like domains (Tie)-2 receptors 
expressed on the surface of endothelial cells. In the angiogenic vessel, 
endothelial Tie-2 expression is localized behind the leading edge, 
coensiding with the location of vessel maturation [44]. In turn, Ang-2 is 
expressed by endothelial cells, located at the leading edge of sprouting 
vessels [45]. Studies show that Ang-2 competes with Ang-1 for Tie-2. Also 
pericytes express Tie-2 and in the presence of high levels of Ang-2 (binds 
to Tie-2) pericytes dissociate from the endothelial cells and this results in 
the destabilisation of the vessel, an event occurring during angiogenesis 
(see Section 2.2). 
 
Vascular Endothelial Growth Factor (VEGF) is secreted by sprouting 
endothelial cells and leads to the expression of Ang-2 and the suppresssion 
of PDGFR signaling. This, together with MMP degradation of the shared 
basal membrane, can explain the loss of pericytes during the initial phase 
of angiogenesis. In the context of pericytes VEGF has multiple functions. 
Under hypoxic conditions VEGF directly induces proliferation and 
migration of pericytes [46]. Pericytes also secrete low levels of VEGF that 
acts as a survival mechanism for endothelial cells in a juxtacrine/paracrine 
manner and maintains endothelial homeostasis [34, 47]. 
Other pathways, ligands and receptors are also important for the 
functionality of pericytes eg. Notch-3 and Ephrin-B2 [48]. 
 
In tumors, the role of pericytes is somewhat unclear. It abides to logic that 
the function of pericytes in tumors would be to stabilize the newly forming 
tumor blood vessels, sending survival signals to the endothelial cells. 
However, studies show that pericyte coverage of tumor vasculature is 
variable, ranging all the way down to 10% in eg. Glioblastoma [49]. 
Overall, factors secreted by tumors appear to be sufficient for endothelial 
survival.  
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All in all, pericytes are an important part of the machinery governing vessel 
homeostasis and blood brain barrier integrity. However, their role in tumor 
vasculature remains to be elucidated. 
 
 
1.4 Endothelial cells 
 
Endothelial cells constitute the innermost layer of all blood vessels in the 
body and are the cells in focus for this thesis. Upon initiation of migration 
they exhibit protruding, growth factor seeking filopodia and a ruffled 
membrane at the leading edge called lamellipodia in vitro [50-52]. 
Endothelial cells constitutively express multiple markers, shown in Table 1, 
but other markers exist, expressed upon induction or on organ-specific 
endothelia [53].  
 
During embryonic development, blood vessel formation is one of the 
earliest events of organogenesis. Mesodermal angioblasts are endothelial 
cell precursors that differentiate into endothelial cells in response to e.g. 
VEGF [54]. This is a process called vasculogenesis, further described in 
Section 2.1. From this nascent primitive plexus more vessels are sprouted 
through angiogenesis, further described in Section 2.2.  
 
Endothelial cells show remarkable heterogeneity for being a single cell 
kind. The surrounding cells and matrix shape the ECs and their behavior. 
Examples of ECs that have gained very ”organ”-specific characteristics are 
the ECs of the High Endothelial Venules (HEVs), the bone marrow 
endothelium and the cerebral endothelium. Also, these specialized ECs 
have been showed to secrete factors important for certain organs to 
develop properly, such as the pancreas [55].  
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1.4.1 Endothelial cells in this thesis.  
 
Mouse Aortic Endothelial (MAE) cells are spontaneously immortalized 
murine endothelial cells of the aorta [56]. Our MAE cells have a C57/B6 
background and are described in Levchenko et al 2003 [57]. MAE cells 
express no (by Western Blot) detectable levels of Amot [58].  
 
Bovine Capillary Endothelial (BCE) cells are, as the name implies, capillary 
endothelial cells of bovine origin. We have used them both with and 
without being immortalized with hTERT [59, 60]. BCE cells express both 
isoforms of Amot [61, 62].  
 
Mile Sven (MS)-1 cells (ATCC: CRL-2279) are SV40 Large T transformed 
murine pancreatic islet endothelial cells, also from a C57/B6 background  
[63]. MS-1 cells express primarily the p80-Amot isoform [64]. 
 
Polyoma Middle T Endothelial Cells (PmT-ECs) have been described in 
publications by our group and are used in Paper I and III of this thesis [61, 
65-67]. It is a stable amot negative murine endothelial cell line with a 
C57/B6 background. It was procured from embryoid bodies of wild-type or 
amot negative mice that had been differentiated into ECs and were 
subsequently immortalized with Polyoma Middle T [61, 68]. Wild-type 
PmT-ECs express both isoforms of Amot [61, 67]. 
 
 
2 Blood vessels 
 
In a healthy individual, blood vessels follow a hierarchy where larger vessel like 
arteries and veins branch into smaller arterioles and venules, which in turn branch 
out into capillaries. Capillaries, the smallest blood vessels in the body, consist of 
several layers. Surrounding the circulating erythrocytes and plasma is the innermost 
layer, the endothelial cells. Each EC connects to the other via Tight Junctions (TJs) 
and Gap junctions [32, 43]. The ECs secrete a basal membrane on which they are 
attached. Sharing, and secreting, the same membrane are the pericytes, sheathing 
and stabilizing the endothelial tube. Inter-neurons, regulating vascular tone, are 
connected and in the case of cerebral vasculature, astrocytes encase the capillary. 
Apart from the shared basement membranes, gap junctions between the cells allow 
for inter-cell communication.  
 
Tumor vessels are abnormal in both architecture and structure. Ignoring the 
hierarchy of the vascular system they also tend to be dilated, tortuous, and 
hyperpermeable [69]. 
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2.1 Vasculogenesis 
 
The process of vasculogenesis (Figure 4 and 8b) in mice is very well 
described in a review article by Chung & Ferrara, published last year [70]. 
It describes the mesodermal-derived hemangioblast, which migrates from 
the primitive streak into e.g. the yolk sac and the intra and extra embryonic 
ectoderm. As enough cells have aggregated into blood islands they join to 
form a primary capillary plexus. In parallel, the dorsal aorta and cardinal 
vein are formed and together they form a primitive vascular network, 
further branched and matured via angiogenesis (see Section 2.2). The 
blood vessels undergo maturation and stabilization upon the recruitment of 
mural cells. This process is illustrated in more detail in Figure 4 below.  
 
 
 
2.2 Angiogenesis 
 
The process of angiogenesis occurs when new blood vessels are sprouted 
from a pre-existing vessel (Figure 8a and in more detail in Figure 5). In 
response to external angiogenic stimuli (e.g. Ang-2) mural cells and 
pericytes let go of the ECs. They start secreting proteases like MMPs to 
Figure 4. Developmental vasculogenesis and angiogenesis, as described by Chung & Ferrara. 2011. Annu Rev Cell 
Dev Biol: ”(a) In the embryo, the hemangioblast precursor characterized by Flk-1 expression can give rise to cells 
of the hematopoietic lineage and to Notch signaling–specified angioblasts. (b) Notch signaling further contributes 
to arterial-venous (A-V) fate specification by promoting arterial cell fate. (c) Intraembryonic angioblasts aggregate 
directly into the dorsal aorta or cardinal vein, a process mediated by vascular endothelial growth factor (VEGF), 
Sonic hedgehog (SHH), and Notch signaling. In the yolk sac, angioblasts fuse in formation of a vascular plexus; 
expression of arterial Ephrin-B2 and venous EphB4 function in A-V specification. (d) Following vascular 
remodeling, mural cells are recruited for stabilization and maturation of nascent vessels; this process is mediated 
by platelet-derived growth factor B (PDGF-B), transforming growth factor β (TGF-β), and angiopoietin-1 (ANG-1) 
signaling.” 
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digest the surrounding extracellular matrix (ECM). The angiogenic factors 
surrounding the vessel and released by the ECM degradation triggers a 
dilation of the vessel and the TJs on the ECs are gradually lost. The 
resulting leakage of plasma proteins from the vessels into the ECM 
deprived, angiogenic area, functions as a provisional fluid matrix on which 
the ECs can migrate. As the ECs start migrating toward a gradient of growth 
factors such as VEGF and bFGF one EC takes the lead, probing the way 
[71-73]. This tip cell is unique, with several differences both in 
morphology and markers. Trailing behind are the stalk cells, which 
proliferate continuously in order to maintain the connection between the 
mother vessel and the sprout [71, 74]. As the sprout reaches another blood 
vessel (or the same one further up or downstream) the vessels fuse through 
the process of anastomosis [71]. Upon the initiation of blood flow the ECs 
resume their quiescent state and switch to secreting factors attracting 
pericytes and allow for the vessel to mature. In the absence of circulation 
after anastomosis, the sprouted vessel will not survive. This process, called 
vessel pruning/regression, is caused by mechanisms that still remain to be 
elucidated [75, 76].    
 
 
 
Figure 5. Sprouting angiogenesis in more detail. From Adams & Alitalo. 2007. Nat Rev Mol Cell Biol.  
 
2.2.1 Physiological angiogenesis 
 
After the primary vascular plexus (see Section 2.1) has been formed 
angiogenesis is the main process through which the capillary network is 
branched and fully developed during embryogenesis [77].  
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Angiogenesisn is primarily avtive to expand the vascular network in 
growing tissues. However, angiogenesis is still important during; wound 
healing, the ovarian cycle and endometrial renewal prior to menstruation. 
During pregnancy is also essential for the correct formation of the placenta 
and the growth and vascularization of the uterus [78, 79]. 
 
 
2.2.2 Angiogenesis in cancer/Pathological angiogenesis 
 
Blood vessels are essential for tissue survival; hence insufficient 
angiogenesis is associated with pathological conditions. Excessive 
angiogenesis is also a problem and is usually coupled to proliferative 
diseases such as cancer. The word cloud in Figure 6 shows diseases 
associated with either side of pathological angiogenesis imbalance, black 
representing Excessive angiogenesis and blue insufficient [80].  
 
 
 
 
2.3 Intussusception 
 
Intussusception is a process of blood vessel formation with many names; 
non-sprouting angiogenesis, longitudinal splitting, luminal division and 
splitting angiogenesis. As the names indicate it is the process when one 
capillary splits into two, see Figure 7 and 8c. Endothelial cells of the 
capillary wall invaginate into the luminal space of the vessel and form 
islands of endothelial cells, spreading along the vessel direction forming 
‘tissue pillars’ and ending in splitting the vessel along the longitudinal axis 
Figure 6. Wordcloud on angiogenesis-associated diseases, excessive (black), insufficient (blue).  
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[55, 76, 81]. Intussusception has been found in a multitude of 
physiological processes (like the formation of the pulmonary capillary bed) 
and also during pathological conditions [82]. 
 
The advantages of intussusception over vasculogenesis and angiogenesis is 
that blood vessels are formed more rapidly and in a more economic 
manner (energetically and metabolically) since the need for proliferation, 
basement membrane degradation and invasion into surrounding tissues is 
not as extensive [55]. 
 
 
 
 
 
 
 
 
 
 
Figure 7. The formation of new blood vessels through intussusception. From Djonov et al. 
2003. Cell Tissue Res. 
 
 
2.4 Other means of blood vessel formation 
 
Vasculogenic mimicry (Figure 8e) is a process where tumor cells line part 
of a blood vessel, but examples of complete tubular and patterned matrix 
type of blood containing vessel have been reported. This type of 
vascularity has been seen in several cancer types such as melanomas, 
breast carcinomas, ovarian and prostatic carcinoma and many more [76, 
81].    
 
Vessel co-option (Figure 8d) is not a process of blood vessel formation per 
se. However, it is a solution for tumors to attain nutrients and oxygen 
without the need of de-novo formation of vessels. This is accomplished by 
the tumors growing along existing vessels, relying on diffusion of gases and 
molecules to sustain them. Logically, vessel co-option is therefore mostly 
seen in well-vascularized tissues like brain and lung [81]. Since this way of 
sustaining tumor growth is independent of angiogenic triggers, tumors 
relying mostly on vessel co-option do not respond to anti-angiogenic 
therapy.  
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3 Angiomotin 
 
Angiomotin (also known as KIAA1071, AF286598) was discovered in the 
Holmgren lab in 2001 through a yeast-two-hybrid screen for novel Angiostatin 
receptors [83]. The protein was found to be expressed in blood vessels of different 
cancer-types and to be important for angiogenesis occurring during embryonic 
development [61, 68]. Upon overexpression, the gene caused increased migration 
in micro capillary cells. Logically, it was named Angiomotin from the latin word 
angio for vessel and motus for motility.  
 
The Motin family of proteins consists of Angiomotin (Amot) [84], [85] [65], [86], 
[61], [87], [88], [67], [62], [58], [83], Angiomotin-like 1 (AmotL1) [64], [89], [90], 
Figure 8. The different means of blood vessel formation. From Carmeliet & Jain. 2011. Nature. 
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[62],[91] and Angiomotin-like 2 (AmotL2) [92], [93], [94], [95]. Our and other labs 
have shown that Angiomotin exists in two different isoforms, called p80- and p130-
Amot [86], [67], [96]. The same holds true for the rest of the family, bringing the 
total number of proteins in the family up to six, in humans. Whether these isoforms 
are formed due to alternative splicing or have completely different promoters is 
currently under discussion and investigation, but to date the splice isoform 
hypothesis remains, as reported by Moreau et al in 2005.  
 
 
3.1 General structure of the Motin family 
 
Structure-wise, the common denominator for the family is that all members 
have a conserved coil-coiled domain and a PDZ-binding domain, as 
illustrated in Figure 9. The longer isoforms also sport an N-terminal 
proline- and glutamine-rich domain, containing a PPXY-motif [89], [67], 
[95]. Angiomotin is the only member that also contains an Angiostatin-
binding domain (see Figure 9). These domains all play a role in 
interactions, effects and localizations of the proteins. I will briefly 
summarize the importance of each domain in this section, but more 
detailed information on interacting partners can be found in Section 4. 
 
 
Figure 9. Schematic structure of the Motin family.  
 
For the remainder of this section, the data discussed is focused upon Amot. 
However, considering the high conservation of the sequences and the 
similarities in binding proteins, the data in this section is also of interest for 
AmotL1 and AmotL2.  
 
 
3.1.1 The Coiled-coil Domain 
 
An intra-membrane localization of Angiomotin has long been debated 
back and forth. The Holmgren lab argues for a part of the protein being 
exposed on the cell surface, whereas structure prediction analysis tools 
(and believers thereof) state that the amino acid sequence does not 
comprise a trans-membrane domain [95]. The reasoning behind the 
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existence of an extracellular domain on Amot is that; 1) It binds to 
Angiostatin, a secreted, extracellular protein. Upon binding to Amot, the 
complex is internalized, a phenomenon not seen in the control 
experiments [83], 2) Anti-Amot antibodies can bind to the cell surface [62, 
88, 97], 3) When biotinylating all surface proteins, Amot is biotinylated 
[62] and 4) Amot is degraded by extracellular trypsin, while intracellular 
proteins are not [62]. Since the both the PPXY-motifs (N-terminal) and the 
PDZ-binding motif (C-terminal) are needed for some of Amot's intracellular 
protein-protein interactions (more on this in Section 4) they need to be 
located intra-cellularly [65, 67]. The conclusion in the Holmgren lab is that 
the exposed part of Amot may span from the coiled-coil domain to the 
Angiostatin binding domain.  
 
While trying to crystallize Amot, alone and with binding partners, multiple 
truncated variants of Amot were produced. Amongst them was the isolated 
coiled-coil domain, which proved to be the most stable and soluble part of 
the protein. From studies conducted by the Holmgren group in 
collaboration with the Swedish company BioInvent, I had access to a 
limited amount an anti-Angiomotin IgG as well as a control [97]. 
Exploratory gel filtration showed that the anti-Angiomotin IgG bound to the 
Amot coiled-coil domain, whereas the control did not (unpublished data, 
Figure 10). This data shows the binding domain of the anti-Amot antibody 
and may be interpreted as some part of the coiled-coil domain being 
exposed on the cell surface. We therefore moved on to looking more 
closely at the coiled-coil domain. We (unpublished) and Wells et al (2006) 
have found that Angiomotin has predicted structural similarities to the 
(Bin/Amphiphysin/Rvs) (BAR) domain of Amphiphysin, which is best 
visualized when Amot is modeled upon the structure of Amphiphysin (see 
Figure 11) [87]. In short, BAR domains either binds to curved membrane 
structures or bends the associated membrane to a curve of its liking [98]. 
BAR domains are also common for interaction with other BAR domain 
proteins and this is also the case for Amot, a topic covered in Section 4. 
After further investigation, Wells et al now call the Amot coiled-coil 
domain for Amot coiled-coil homology (ACCH) and declares it a 
conserved lipid-binding domain, concluding that the coiled-coil domain of 
Amot binds to cholesterol-rich membranes [99].  
 
 
 
 
 
 
 
 
 
MAKING ENDOTHELIAL CELLS MOVE – A STUDY OF ANGIOMOTIN AND BINDING PARTNERS 
 
 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Exploratory gel filtration on purified Amot coiled-coil domain and 
the anti-Amot IgG. Arrows indicate sample peak, showing that the 
combination of Amot and the antibody elutes later then either alone, 
suggesting that they form a larger complex. Unpublished data. 
Figure 11. Overlay of Amot amino acid sequence on the crystal structure 
of Amphiphysin BAR domain. From Wells et al. 2006. Cell. 
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3.1.2 The PDZ-binding motif 
 
In general, PDZ binding motifs have one goal in life: to bind a PDZ-
domain and vice versa, meaning that they are certain protein:protein 
interaction points. More specifically, PDZ domains are shown to mediate 
the formation of larger protein complexes and to be crucial for correct 
localization of membrane proteins [100, 101]. The PDZ-binding motif of 
Amot is a short four amino acid sequence at the C-terminus; EYLI (AmotL1; 
EVLI, AmotL2; EILI). We have shown that the PDZ-binding motif of Amot is 
essential for endothelial cell migration and that the loss of the motif leads 
to inhibition of cellular migration, embryonic lethality and impaired 
endothelial migration during zebrafish vascular development [65], [58], 
[57]. Interestingly, the motif is essential for the TJ localization of p80-Amot 
but not for p130-Amot [86].  
 
 
3.1.3 The N-terminal domain 
 
As mentioned above the N-terminal domain is a proline- and glutamine-
rich domain unique to the longer isoforms of the Motin family. It contains a 
PPXY-motif, capable of interacting with WW domains of other proteins, 
like those of; MAGI, NEDD4 and YAP/TAZ [62, 102-104]. Unlike the PDZ-
binding motif, the N-terminal domain of p130-Amot is essential for its 
localization to TJs and interaction with actin fibers [67].  
 
 
3.2 The two isoforms: p80- and p130-Amot 
 
When Angiomotin was first discovered it was the p80-Amot isoform that 
was characterized. Troyanovsky et al. found that the protein localizes to 
the lamellipodia of migrating cells and later it was also shown to be 
present in cell-cell contacts, overlapping with tight junction proteins like 
ZO-1 [62, 83, 87]. The p130-Amot isoform was also characterized in the 
Holmgren lab [67, 86], with a 409 amino acid (aa) long N-terminal 
domain added to what was known as p80-Amot (Figure 9) [62, 67, 86]. 
Eventhough both isoforms localizes to TJs (but are not essential for TJ 
formation) p130-Amot does so to a larger extent but also forms punctated 
patterns throughout the cytoplasm upon IF staining, colocalizing with actin 
[67]. As more data compiled, multiple differences between p80-Amot and 
p130-Amot were seen; (1) p130-Amot has an actin binding N-terminal 
domain, p80-Amot does not, (2) Overexpression of p130-Amot leads to 
flatter ECs than p80-Amot, (3) p80-Amot ECs respond to anti-migratory 
signals by Angiostatin while p130-Amot ECs do not [67, 86].  
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By co-immunoprecipitation Ernkvist et al. found that the two isoforms can 
homo-oligomerize and also form hetero-oligomers with eachother through 
their mutual coiled-coil domains [86]. This piece of information was of 
particular interest when they found that the relative expression levels of 
p80-Amot to p130-Amot dictate cell behavior. In an overexpression setting 
in vitro, induced expression of p80-Amot removes p130-Amot from cell-
cell junctions, thus destabilizing the junctions and promoting a migratory 
phenotype. This indicated that the hetero-oligomer does not seem to 
function in the tight junctions, possibly due to steric hindrance or blocking 
of a binding site by the oligomerization. Taken together, the data shows 
that the ratio of the isoforms dictates cell phenotype and that p80-Amot 
function is dominant over the function of p130-Amot. Differential 
expression of the isoforms can be seen in several situations, such as during 
retinal angiogenesis after birth in mice and during embryonic 
development. Retinal angiogenesis occurs postnatally in mice and studies 
show a divergence in expression the two Amot isoforms p80 and p130. 
p80-Amot is expressed during post-natal day (P)3-P7 whereas p130-Amot 
is expressed at P7-9 and in adult, fully developed, retinas [86]. During 
embryonic development p80-Amot is expressed during E5-19 while p130-
Amot does not appear to be expressed at all. However, in the placenta 
p130 is expressed at E13-16, while p80-Amot is constitutively expressed 
[67].  
 
 
3.3 Angiomotin in Angiogenesis 
 
Angiogenesis depends on endothelial cell migration and as such we have 
studied Angiomotin in vitro and in vivo in order to understand its function 
and importance.  
 
The Holmgren lab has used the embryoid body model system to study tube 
formation through both vasculogenesis and angiogenesis. Embryonic stem 
cells from amot negative and wild-type mice were allowed to differentiate 
and form a primitive vascular plexus and initial capillaries. amot negative 
EB ECs did not sprout in response to VEGF stimulation, indicating either a 
loss of VEGF responsiveness or malfunctioning EC migration [61]. 
 
As mentioned in Section 1.4.1, a stable amot negative endothelial cell line 
was procured from the EBs, called PmT-EC. These cells exhibit a 
disorganized actin cytoskeleton, disrupted focal adhesions and a loss of 
polarity. These results coincide with what we observe in both MS-1 and 
BCE cells upon amot mRNA expression knock-down with siRNA [61, 66]. 
Furthermore, the amot negative PmT-ECs display a significant increase in 
membrane protrusions rapidly forming and retracting as well as several 
lamellipodia and a depolarized phenotype. In Paper I, this phenomenon is 
explained by a misslocalization of RhoA acitivty leading to actin being 
polymerized at random throughout the membrane [65]. Both the stable 
MAKING ENDOTHELIAL CELLS MOVE – A STUDY OF ANGIOMOTIN AND BINDING PARTNERS 
 
 20 
and siRNA treated amot negative ECs show a marked decrease in 
directional migration in response to growth factor stimuli, both as a sheath 
and as single cells [61, 62, 64, 83].  
 
To date we have studied the loss of amot expression in both zebrafish (zf) 
and mice. In zf, the antisense morpholino (MO) technique has been 
utilized in order to block and degrade amot mRNA. In mice, we have used 
a conventional knock-out mouse strain, which has now been replaced by a 
conditional knock-out strain currently being bred to be studied [61, 68]. 
 
In the conventional amot negative mouse model (C57/B6 backcross) loss of 
amot expression leads to dilation of cranial vessels and an insufficient 
vascularization of the intersomitic region [61]. As a result 75% of the 
conventional amot negative mice die in utero at E11-E11.5 indicating that 
amot plays an important role during embryonic vascular development [61, 
68].  
 
As shown in Aase et al 2007 and Ernkvist et al 2009 the loss of amot 
mRNA expression in zebrafish embryos leads to malformation of the inter-
somitic/segmental vessels (ISVs, see Figure 13 for anatomy) [61, 65, 68]. 
The ISVs sprout from the dorsal aorta, but come to a halt, instead of 
continued dorsal migration all the way between the somites and 
subsequent anastomosis to form the Dorsal Longitudinal Anastomosing 
Vessel (DLAV). Also, a dilation of the cranial arteries is observed, 
corresponding to our findings in mice.  
 
 
 
Figure 12. Anatomy of the zebrafish embryo. Top: Brightfield image. 
Middle: Fluorescence image of transgenic zf. Green: ECs expressing 
GFP under the fli promotor. Red: Erytrocytes. Bottom: Fluorescence 
image zoomed in on somites. Vessels indicated. 
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In 2006 and 2012 the Holmgren, Kiessling and Cavallo labs show that 
DNA vaccination against human p80-Amot in both transplanted xenograft 
breast cancer tumors and in spontaneously developed mammary 
carcinomas in mice (Balb/C background), leads to both tumor protection 
and a marked reduction in tumor growth in already established tumors [84, 
88]. Futhermore, in Paper III, we show that loss of amot expression leads to 
impaired pathological angiogenesis [66]. 
 
 
3.4 Tissue expression 
 
Using western and northern blot analysis the expression of Amot has been 
detected in various tissues. In mice Amot has been found to be expressed 
in the developing embryo and in the retina of neonatal pups [68, 86]. More 
specifically Shimono and Behringer found that: “amot is expressed in a 
dynamic, region-specific pattern in the Visceral Endoderm (VE) just before 
and during gastrulation. Our findings suggest that amot is required in the 
Anterior VE for movement away from the epiblast and association with the 
proximally located extra-embryonic ectoderm”. As mentioned in Section 
3.2, Amot expression has also been seen during retinal angiogenesis in 
neonatal mouse pups and in placenta (cytotrophoblasts). In the adult, Amot 
expression has been reported in brain, heart and retina, but is also 
expressed to a lesser degree in liver and lungs [67]. In humans, Amot 
expression was studied in fetal and adult tissues and found to be high in 
fetal kidneys, placenta and brain and lower in lungs. In adults Amot 
expression was high in muscle tissue, placenta, brain and kidneys while 
lower in the heart and pancreas [83]. 
 
Eventhough most data is collected in blood vessels and endothelial cells, 
Amot expression is not restricted to endothelial tissue. In Aase et al. 2007, 
Amot expression was also found in Rathke’s pouch, a collection of 
epithelial cells destined to become the anterior pituitary (murine)[61]. 
Heller et al (2010) state: “Although Amot expression is low in most 
differentiated epithelial cells, it is strongly up-regulated during epithelial 
migration programs during developmental processes, such as trophoblast 
extension and anterior visceral endoderm formation.”[99] Expression in 
epithelial cells has also been reported in other articles (e.g. Paper II), 
indicating that Amot is not a protein unique to the endothelium but 
remains a significant part of endothelial signaling [85, 87, 105]. 
 
Earlier data from The Human Protein Atlas project (protein expression 
analysis on human tissue; www.proteinatlas.org) showed that Amot was 
preferentially expressed in blood vessels and in brain tissue, corroborating 
our findings. However, on the current webpage, all data on Amot has been 
removed, pending new analysis. In order to get more, independent tissue 
expression data on Amot one must turn to other sources. Today, the 
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Internet harbors several ambitious databases. One such is GeneSapiens.org 
(FIMM, Turku, Finland). It collects human microarray gene expression data 
from cell lines, healthy tissue as well as patient material. amot expression 
in healthy tissue is depicted in Figure 13.  
 
 
Searching literature on Amot expression in pathologies reveals that 
Kaposi’s sarcoma tumor vessels express Amot but the vessels of normal 
tissue do not and that Peripheral Blood Mononuclear Cells (PBMCs) of 
Rheumatoid Arthritis patients express Amot at a higher level than 
osteoarthritis patients [83, 106]. Also, upon looking at amot gene 
expression in tumor tissue, Jiang et al found that amot is expressed at 
significantly higher levels in human breast carcinomas compared to normal 
breast tissue [107]. In mice, Amot expression was found in the blood 
vessels of spontaneously formed lobular mammary carcinomas in 
transgenic BALB/c mice, but not in normal breast tissue [88]. Lastly, 
GeneSapiens.org can also provide expression data on pathological 
conditions, depicted in Figure 14. 
 
Figure 13. The relative angiomotin mRNA expression in samples from different tissues. Gene array results pooled 
and compiled by GeneSapiens.org for AMOT/ENSG00000126016, 2012-07-31 
MAKING ENDOTHELIAL CELLS MOVE – A STUDY OF ANGIOMOTIN AND BINDING PARTNERS 
 
 23 
 
Figure 14. The relative angiomotin mRNA expression in samples from different pathological conditions. 
Gene array results pooled and compiled by GeneSapiens.org for AMOT/ENSG00000126016, 2012-07-31. 
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Taking all of this data together, Amot is postulated to be useful as a 
prognostic marker for aggressive disease and patient survival as well as a 
therapeutic target. It follow suit that anti-Angiomotin therapy should be 
attempted. More on that in Section 6.  
 
4 Angiomotin Binding Partners 
 
The proteins found to bind to Amot are all somehow involved in cell polarity and 
migration and sometimes also proliferation, mostly fitting the known function of 
Amot. Cell polarity has mostly been studied using epithelial cells and Drosophila 
Melanogaster (fruit fly) or Caenorhabditis Elegans (nematode) as model systems in 
vitro and in vivo. As a consequence, nomenclature can be a jungle. When drawing 
conclusions, I will try to keep to the official mammalian/human names of the 
proteins, however, when stating what has been found both unofficial names and fly 
names of the orthologs might frequent the text. To make inter-species translation 
quicker, please refer to POST-IT number 1. Apart from the proteins mentioned in 
this section the PDZ-binding motif of Amot has been reported to bind Filamin A 
and PTN13 [65]. 
 
 
4.1 Cell polarity 
 
As most topics in this thesis, cell polarity could fill a few theses on its own. 
Cell polarity has mostly been studied in epithelial cells, which have very 
distinct polarity compartments; Basal (facing ECM, the bottom), 
basolateral/lateral and Apical (facing the lumen, the top). Eventhough 
Inter-species Translation POST-IT 
- Amot Binding Partner Orthologs 
Mammals D. Melanogaster   (INADl/PATJ) InaD-like protein Discs Lost (Dlt) (MPDZ/MUPP1) Multi-PDZ domain protein Patj (Patj) (Plekhg5/Syx1) Plextrin homology domain 5 CG42674 (MPP5/Pals1) MAGUK p55 subfamily member 5-A Stardust (Std)  (Crb3) Crumbs homology domain 3 Crumbs (Crb) (Par-3) Partitioning defective 3 homolog Bazooka (Baz) (Lin7C) Protein lin-7 homolog 3 Veli (Veli) (NF-2) Neurofibromatosis-2/Merlin Merlin (Mer) 
 1 
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endothelial cells lack these exact compartments, conclusions from 
epithelial cells can be translated into ECs. As such, the data presented on 
the functions of Amot binding partners will most often come from 
epithelial cell studies. 
 
Three major polarity complexes participate in the establishment of apical-
basal polarity; The Crumbs Complex, the PAR complex and the Scribble 
complex (Figure 15) [108]. The Crumbs complex (see Section 4.2.3.) is 
required for the establishment of the apical membrane and comprises 
Crumbs homology domain 3 (Crb3), MAGUK p55 subfamily member 5-A 
(MPP5, also known as Pals1) and InaD-like protein (InaDl, also known as 
Patj). The PAR complex is more involved in the lateral compartment and 
consists of partitioning defective 3 (Par3), Par6, atypical Protein Kinase C 
(aPKC) and Cell division control 42 (Cdc42). The Scribble complex is the 
union of Scribble (Scrib), Lethal Giant Larvae homologue (LGL) and Discs 
LarGe homologue (DLG). The complex defines the basolateral domain of 
epithelial cells. Together these three complexes interact with each other, 
adhesion proteins and to the actin cytoskeleton to organize and maintain 
junctional complexes, polarity and, to some extent, migration [108, 109].  
 
 
 
 
Figure 15. The major polarity complexes in epithelial polarity. From  Martin-Belmonte & Perez-Moreno. Nature 
Reviews Cancer. 2012. 
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4.2 The CRB3 Complex 
4.2.1 PATJ and MUPP1 
 
Pals-1 associated tight junction protein (Patj) and Multi PDZ domain 
protein 1 (Mupp1) are homologous and possibly paralogous multi-PDZ 
domain proteins where the PDZ domains (10 and 13 respectively) are 
positioned like beads on a string after an L27 domain (Figure 16). They are 
scaffolds, bringing together proteins with PDZ-binding motifs and L27 
domains into larger complexes. 
 
  
 
 
Figure 16. Domain structure of Mupp1 and Patj. Percentages indicate level of identity between domain 
sequences. From Adachi et al. 2009. Mol Cell Biol. 
 
 
The L27 domain of Patj and Mupp1 interacts with the L27 domain of Pals1, 
which in turn binds to Protein Lin 7 homology 3 (Lin7) and Crb3 [110]. 
The various PDZ domains have been mapped for binding to several 
polarity TJ and adherens junction (AJ) proteins like Claudin-1, Junctional 
Adhesion Molecule-1 (JAM-1), Zona Occludens (ZO)-1 and -3, nectins and 
Par-6 [111, 112].  
 
Shin et al (2007) speculate that Patj and accompanying complex localizes 
to the leading edge of a migrating cell and then recruits atypical Protein 
Kinase C (aPKC) and Par3, thereby redirecting microtubule formation. This 
theory is similar to the one we draw in Paper I [113].  
 
Since Patj and Mupp1 have matching domain structures, binding partners 
and cellular expression but somewhat diverging function, the difference 
between the two has been investigated. Adashi et al. attempt to explain this 
by dissimilar affinities for the different binding partners [111]. 
 
In Paper I (and confirmed in Wells et al 2006 in epithelial cells) we identify 
Patj and Mupp1 as binding partners of Amot. Further investigation showed 
that Amot bound to the third PDZ domain (PDZ3) of Patj and that AmotL1 
MAKING ENDOTHELIAL CELLS MOVE – A STUDY OF ANGIOMOTIN AND BINDING PARTNERS 
 
 27 
and AmotL2 bound to PDZ 1 and 2, respectively [65]. We further show 
that PDZ10 binds to the RhoGEF Plexstrin homology domain 5 (Plekhg5, 
also known as Syx1) [114]. Taken together with the findings of a disruption 
of the complex during migration, we propose a model where Amot and 
Patj are localized to the leading edge of a migrating cell, recruiting Syx1 
and actin polymerization to the correct place for generating movement. 
 
 
4.2.2 PALS1 
 
Pals1, called Nagie oko in ZF, consists of: two L27 domains, a PDZ 
domain, an SH3 domain, a band 4.1-binding domain, and a GUK domain. 
The two L27 domains mediate the interaction with Patj and Lin7. The PDZ 
domain binds Crb3 and within the N-terminus hides an internal motif (U1 
domain) binding to Par6, connecting the Crumbs complex to the Par 
complex [115-117]. 
 
  
4.2.3 CRB3 
 
Crumbs homology domain 3 or Crb3 consists of a large extracellular 
domain, a transmembrane domain and an intracellular domain containing 
one FERM and one PDZ-binding motif. The function of the extracellular 
domain remains to be elucidated, but appears to be of lesser importance 
since only the intracellular domain is enough to rescue the loss of polarity 
caused by crb3 knock-out [118]. The function of the FERM motif remains 
to be elucidated. Unlike the extracellular domain, the FERM domain is of 
greater importance for Crb3 function, as mutation of the domain results in 
severe tight junction disruption [119]. The same holds true for the PDZ-
binding motif, which interacts with Pals1, connecting Crb3 to Patj.  
 
Crb3 is localized to the apical membrane of mammalian epithelial cells 
and is concentrated to TJs. Overexpression of Crb3 leads to an expansion 
of the apical domain and concomitant reduction of the basolateral domain. 
Loss of Patj expression leads to the misslocalization of Crb3 and a 
disruption of TJs, indicating that Crb3 is important for TJs formation and 
that its localization is dependent on Patj and most possibly Pals1 [120]. 
Interestingly, whereas Patj is required for epithelial migration and is 
localized at the leading edge of a migrating cell, Crb3 is not [113]. This 
suggests the entire polarity complex is not present during actual cell 
migration.  
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4.3 Rho GTPase modulators 
 
The Rho GTPases; Rho, Rac and Cdc42, coordinate the machinery of cell 
migration. They modulate the actin cytoskeleton by regulating actin 
polymerization, depolymerization and the activity of actin-associated 
myosin [121]. The RhoGTPases are regulated through cycling between 
GDP-bound (inactive) and GTP-bound (active) state. This binary switch is 
regulated by: Guanine Nucleotide Exchange Factors (GEFs), GTPase 
Activating Proteins (GAPs) and Guanine Nucleotide Dissociation Inhibitors 
(GDIs). GEFs activate the RhoGTPase by exchanging GDP for GTP, GAPs 
inactivate by controlling the shift from GTP to GDP and GDIs interact with 
the GDP-bound and prenylated form of the GTPase, inhibit the 
dissociation of the GDP and control the cycling between the cell 
membrane and the cytosol (See Figure 18) [122].  
 
 
 
 
 
 
 
 
Figure 17. The regulation of RhoGTPases. From Schmidt & Hall 2002. Genes & 
Dev. 
 
 
4.3.1 Plekhg5/Syx1 
 
In Paper I, we find that correctly localized RhoA activity is dependent upon 
Amot expression. We show that Amot binds to Patj/Mupp1, which in turn 
binds to the RhoGEF Plekhg5/Syx1 [65]. Syx1 has been reported to be 
expressed at high levels in brain and heart, two highly vascularized tissues, 
overlapping with that of Amot. We and Garnaas et al. show that syx1 is 
important during developmental angiogenesis in zf and mice and that loss 
of gene expression leads to impaired blood vessel formation, similar to that 
of amot [65, 114]. We show that Syx1 interacts with the PDZ domains on 
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Patj, indicating the involvement of the Syx1 PDZ-binding motif. Horowitz 
et al. show that high Syx1 expression increases endothelial cell migration 
and tube formation and that this effect depends upon the PDZ-binding 
motif [123]. Taken together, we propose that Amot localizes to the 
lamellipodia at the leading edge of a cell, bringing with it Patj and Syx1 
and by these interactions localizes RhoA activity and promotes endothelial 
cell migration.  
 
 
4.3.2 ARHGAP17/Rich-1 
 
ARHGAP17 or RhoGAP Interacting with CIP4 Homologues (Rich-1) is a 
RhoGAP found to regulate the activity of both Cdc42 and Rac1, the other 
two members of the RhoGTPase family, promoting the formation of 
filopodia and lamellipodia, respectively [124]. Rich-1 contains a coiled-
coil domain encompassing a BAR domain, a RhoGAP domain, a proline-
rich domain and a C-terminal PDZ-binding motif [125]. Wells et al found 
that Rich1 is important for epithelial cell TJ formation by showing that loss 
of Rich1 expression leads to the disruption of TJs. They also find an 
interaction between the BAR domain of Rich1 to the coiled-coil/Bar-
domain of Amot [87]. In mammals, Rich1 exists in several isoforms, one of 
which is Rich-1B. It has been suggested that Rich-1B controls vesicle 
formation or membrane trafficking [124]. This is of interest since BAR 
domain proteins may directly regulate vesicle formation and since Amot 
has been shown to localize to vesicular structures [83, 126]. This, together 
with the TJ localization and association of both proteins has led to the 
theory of Amot and Rich1 to function as a means for shuttling tight 
junctions proteins from the golgi to the cell membrane or from the 
membrane into endosomes [127].  
 
 
4.4 Merlin 
 
Apart from being the name of a legendary wizard, Merlin (NF-2, Mer in 
Drosophila) is also the name of an Ezrin, Radixin, Moesin (ERM)-related 
protein [128]. As do most proteins, Merlin has several aliases, the best 
known being Neurofibromatosis type 2 (NF-2), which is also the name of 
the gene encoding the protein. Merlin is a tumor suppressor (TS) and is 
unique in that no other ERM has been shown to mediate contact inhibition 
of proliferation.  
 
Being a relative to the ERM-proteins, Merlin shares most of their structural 
characteristics; an N-terminal FERM domain and a coiled-coil domain. In 
contrast to ERM-proteins Merlin lacks the C-terminal, hydrophilic, actin-
binding motif. Also, Merlin has two additional motifs, missing in other ERM 
proteins: a conserved Blue box motif within the FERM domain and an N-
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terminal segment. Most TS act through catalytic or DNA-binding domains 
but since Merlin lacks both, the action of Merlin must come through 
binding and modulating other proteins and pathways.  
 
ERM proteins function through conformational changes. In a non-
phosphorylated state the FERM domain and the C-terminus of the ERM-
protein are interacting, forming what in literature is termed the “closed” 
state. Upon Rho kinase phosphorylation this head-to-tail interaction is lost 
(“open” state) and the FERM domain is free to associate to the cytoplasmic 
tails of adhesion molecules such as ICAM-1 and CD44. In turn, the C-
terminal domain is free to interact with actin filaments, making ERM 
proteins (e.g. ezrin) key players in regulating cortical actin homeostasis.  
 
Phosphorylated (Ser518) Merlin binds to and forms heterodimers with 
ERM-proteins like ezrin and localizes to the cell cortex. This 
phosphorylation state is most commonly seen in subconfluent, dividing 
cells. The phosphorylation is mediated by p21-activated kinase (PAK) as a 
consequence of integrin and receptor tyrosine kinase (RTK) signaling. Just 
like with ERM-proteins the phoshorylation of Ser518 is thought to affect the 
interaction between the C-terminus and FERM-domain of Merlin and result 
in the “open” state, mentioned above. 
 
Unphosphorylated is the state at which Merlin mediates contact inhibition 
of proliferation. The dephosphorylation and thus activation (“closed” state) 
of Merlin is mediated by the myosin phosphatase MYPT1–PP1d. Explained 
by its structural composition Merlin localizes to sites of adherens 
molecules and pools of actin. In confluent cells it accumulates in adherens 
junctions, TJs and lamellipodia, a pattern similar to Amot [129]. In 
subconfluent cells it displays a more nuclear localization [130]. In 
Drosophila melanogaster, Merlin interacts with the protein called 
Expanded (downstream of the protocadherin Fat) to inhibit proliferation 
through the Hippo Pathway (see Section 4.5). In mammals, the full story 
needs yet more research in order to be coherent. Merlin activates the 
Hippo pathway and is associated with both TJ and AJ proteins but the exact 
mechanotransductory signals remain to be elucidated [129, 131]. 
 
The interaction between Merlin and Amot is explained in Paper II, where 
we show that Amot and Merlin interact through their mutual coiled-
coil/BAR domains [132]. The same domain used for interacting with Rich1 
(see Section 4.3.2). We postulate that Merlin and Rich1 compete for the 
same binding site on Amot and that this is a regulatory machinery for Rac 
activity. Furthermore, we show that the MAPK pathway activation seen by 
Merlin is dependent on Amot function and interaction.  
 
Contact-mediated inhibition of proliferation is crucial for tissue 
organization, and is one of the mechanisms contributing to the 
development of tumors and cancer. As mentioned in Section 1, it is one of 
the hallmarks of cancer. The anti-migratory phenotype seen in cells 
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overexpressing Merlin is also of interest. In Paper II, we report the 
association of Merlin and Amot in the context of cancer. Cells lacking nf2 
expression developed aggressive tumors. However, upon parallel loss of 
amot expression tumors become less aggressive, explained by reduced 
proliferation in vitro [132]. Merlin has been reported to associate with the 
plasma membrane by binding to phosphoinositides, particularly PIP
2
, 
through six charged residues within the FERM domain that are conserved 
in other ERM proteins [133]. This coincides with lipid affinity of Amot 
coiled-coil domain [133]. The interaction of Merlin with phosphoinositides 
is dispensable for Ser 518 phosphoregulation, but it seems necessary for 
Merlin’s localization to the plasma membrane and for some aspects of 
growth suppression [129].  
 
Studies show two more functions of Merlin that I found of interest. One is 
in promoting the endocytosis of signaling receptors and the other is in 
inhibiting Axl at a transcriptional level [128, 129]. In Paper III, Axl is 
presented to be regulated by amot expression and to have an inverse 
relationship with amot, most easily illustrated by the correlation plot 
between amot and axl in blood vessels, from GeneSapiens.org (Figure 19) 
[66].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Gene expression plot of the correlation of axl and amot expression. 
High amot expression correlated to low axl expression and vice versa. From 
GeneSapiens.org 2012-08-01.  
MAKING ENDOTHELIAL CELLS MOVE – A STUDY OF ANGIOMOTIN AND BINDING PARTNERS 
 
 32 
 
4.5 The Hippo Pathway. Of Flies and Men. 
 
I will dedicate this subsection, to very briefly, introduce the Hippo 
Pathway. The Hippo pathway is a tumor suppressor kinase cascade, which 
controls cell survival and proliferation in Drosophila melanogaster. It is a 
cascade that is conserved and can be found also in mammals. As you may 
know, nomenclature for mammalian and fly proteins differs greatly and for 
your convenience, I have added Post-IT number 2, summarizing the 
different names. 
 
The Hippo Pathway consists of Hippo, which is a member of the Ste20 
family of kinases [134]. Hippo binds to and brings together the proteins 
Salvador (Sav) and the kinase complex of Warts and Mats. Upon Hippo 
pathway activation, Warts phosphorylates the transcriptional co-activator 
Yorkie. This leads to the cytoplasmic retention of Yorkie and a resulting 
expressional suppression of Cyclin E and inhibitor of apoptosis (IAP). Thus, 
activation of the Hippo pathway leads to a reduction in proliferation and 
an increase of apoptosis. In fly, this pathway is crucial during 
development. Consequently, suppression of the hippo pathway leads to 
neoplasia and tumor development [135-137].  
 
In the context of Amot, the hippo pathway is of interest due to publications 
showing that the PPXY motif in the N-terminal domain of p130-Amot binds 
to the WW domain of Yap/Taz (equivalent of Yorkie) and sequesters it in 
the cytoplasm [102, 103, 137, 138]. This hinders Yap/Taz from 
translocating to the nucleus and there exert its gene regulatory function.  
 
Inter-species Translation POST-IT 
- Hippo Pathway Orthologs 
Mammals Drosophila (Mst1/2) Serine/threonine-protein kinase 3/4 Hippo (Hpo) (WW45) Protein salvador homolog 1 Salvador (Sav) (Lats1/2) Serine/threonine-protein kinase Lats1/2 Warts (Wts) (YAP) Yes-assoiciated protein  Yorkie (Yki) (TAZ) Transcriptional co-activator with PDZ-binding motif Yorkie (Yki) (MOB1A/B) Mob kinase activator 1 A/B Mats (Mats) (TEF-1) Transcriptional Enhancer Factor-1 Scalloped (Sd) (FDM6) Expanded equivalent Expanded (Ex) 
 2 
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Furthermore, Merlin, an Amot binding partner (see Section 4.4) is also 
involved in the hippo pathway [128, 139-147]. Boggiano and Fehon 
postulate that Yap is recruited to the plasma membrane by AJ proteins like 
α-actinin and to TJ by Amot:Crb3:Patj:Pals1, sequestering it at either 
location and thereby inhibiting its oncogenic activity (Figure 19) [147]. The 
full connection between Merlin, Amot and the Hippo pathway and how 
this may be interconnected with the MAPK signaling pathway, presented in 
Paper II, needs to be further investigated.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 Anti-angiogenic therapy 
 
One of the problems with designing targeted drugs for the actual tumor cells is that 
the tumors cells are very prone to genetic mutation. These rather frequent changes 
both in genotype and phenotype makes it hard to target both a protein that is not 
prone to change and still not attack the surrounding normal tissue. While there still 
are a few successful targeted drugs against e.g. HER-2 in the clinic, other 
possibilities are needed. As mentioned in the earlier sections, tumors need to hook 
up to the vascular network in order to grow beyond 1mm in diameter [148]. The 
hope with anti-angiogenic therapy was to target the process of blood vessel 
formation, kill the tumor vessels and starve the tumors to death. If not that, one 
hoped to at least stop the tumors from growing further and to block metastasis. This 
has been attempted mainly by targeting the pro-angiogenic pathway of VEGF, but 
also HIF1-α [149].   
Figure 19. The Hippo pathway regulation by AJ and TJ as 
proposed by Boggiano and Fehon 2012. Dev. Cell. 
Yap/Taz is recruited to AJs by α-actinin and Merlin and 
by the Crb3:Pals1:Patj:Amot:Merlin complex at TJs. 
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5.1 Endogenous inhibitors 
5.1.1 Thrombospondin 
 
Thrombospondin is a secreted anti-angiogenic protein expressed by a 
variety of cells, including tumor cells. Thrombospondin binds to surface 
receptors, like CD95, CD36 and CD47 and induce apoptosis. It is a 
common finding that upon removal of a primary tumor either by surgery or 
irradiation, the small, inactive metastases start to grow [150]. By 
combining surgery/radiation with Thrombospodin treatment, metastatic 
growth has been shown to be halted [151]. The clinical future of 
Thrombospondin as a drug remains to be seen. However, multiple studies 
are being conducted on Thrombospondin analogues and inhibitors of the 
different Thrombospondin receptors [152-154].  
 
 
5.1.2 Angiostatin 
 
Angiostatin was described by the Folkman lab in 1994 [155]. It was first 
isolated from the urine of tumor bearing mice and was found to inhibit 
both tumor growth and endothelial cell proliferation [156]. Angiostatin is a 
proteolytic fragment of plasminogen fragment and can be even further 
cleaved into smaller components, with different binding partners and 
function. Angiostatin binds to several cell surface receptors apart from 
Angiomotin; ATP-synthase, integrins, annexin II, C-met receptor NG2 
proteoglycan, tissue-type plasminogen activator, chondroitin sulfate 
proteoglycans, and CD26. To test its potential as an anti-angiogenic drug, 
Angiostatin was produced in yeast and showed promise in in vivo-studies. 
However, the poor circulatory half-life, proved to be its downfall. Further 
examination of its receptors/binding partners (like Angiomotin, see Section 
6) continue to this day.  
 
 
5.1.3 Endostatin 
 
Endostatin is one of many derivatives of collagen (arresten, canstatin, 
tumstatin, restin etc.) that has anti-angiogenic capabilities. Endostatin 
originates from Collagen XVIII and inhibits tumor angiogenesis by blocking 
endothelial cell proliferation and tube formation [4, 157, 158]. This is 
accomplished by interaction with several receptors and pathways. In the 
clinic several clinical trials have been conducted with endostatin and 
endostatin analogues, e.g. Endostar has been approved in China for 
treatment of patients with non-small-cell lung cancer [159, 160]. Gene 
therapy regimens like RetinoStat have also been developed, where both 
angiostatin and endostatin expression is induced in the eyes of patients 
with age-related macular degeneration [161].  
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5.2 Inhibitors of angiogenic pathways 
5.2.1 The VEGF Pathway 
 
The VEGF pathway is mainly utilized by endothelial cells, but has an effect 
on other cells types, like renal epithelial cells and monocytes [162, 163]. 
In endothelial cells the VEGF pathway is responsible for cell survival, 
proliferation and migration, making it a key regulator of vasculogenesis 
and angiogenesis [164, 165]. As such, the VEGF pathway has become the 
main target of anti-angiogenic drugs of varying formats and modes of 
action.  
 
There are the anti-VEGF antibodies, like Bevacizumab (Avastin, 
Genentech/Roche), a humanized, monoclonal antibody which binds to 
VEGF and blocks it from binding to its receptor. This drug was the first o its 
kind and has since been approved for multiple cancerous diseases and 
various other disease, like age-related macular degeneration [166]. 
Following in the footsteps of Avastin, there is Ranibizumab (Lucentis, 
Genentech/Novartis), the F'ab fragment version of the antibody mostly 
used in ophthalmologic disorders [167, 168].  
 
Apart from antibodies binding and blocking VEGF, there are molecules, 
like Aflibercept (Zaltrap/Eylea, Sanofi-Aventis/Regeneron 
Pharmaceuticals), which bind to VEGF-A, -B and placental growth factor 
(PlGF) and prevent them from binding and activating their receptors. It has 
been approved for the treatment of wet macular degeneration and shows 
promise in phase III trials for both prostate and metastatic colorectal cancer 
[169]. 
 
Another way of attacking the VEGF pathway is to target the receptors. 
There are anti-VEGFR2 antibodies e.g Ramucirumab (ImClone Systems 
Inc.) that bind to the receptor and inhibit further signaling [170]. Other 
ways of blocking VEGF receptor signaling is to block the intracellular 
kinase domains, which can be done by small molecular inhibitors targeting 
these domains. Imatinib/Imatinib mesilate (Gleevec/Glivec, Novartis) is 
one such drug and it binds to the kinase domain of the receptor tyrosine 
kinases (RTKs) (like VEGF-receptor) and blocks their function by inhibiting 
substrate binding and receptor activation [171]. More small-molecular 
inhibitors of RTKs are e.g.: Sunitinib (Sutent, Pfizer), formerly known as 
SU11248, Sorafenib (Nexavar, Bayer/Onyx Pharmaceuticals) and Vatalanib 
(Bayer Schering and Novartis) [172, 173]. All of these drugs do not only 
have VEGF-receptors as targets but also affect multiple kinases, e.g. PlGF 
and PDGF-Rs too. These drugs have all been approved for the treatment of 
various aggressive carcinomas.  
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5.3 Adverse effects 
 
As mentioned earlier, angiogenesis is not active in the adult, apart from 
wound healing and processes within the female reproductive organs. Most 
endothelial cells are quiescent and as such adverse effects of drugs 
targeting angiogenic, proliferating, endothelial cells were not expected to 
be many nor severe. However, like any drug, anti-angiogenic drugs have 
their share of adverse effects. The nature of these adverse effects range 
from benign to life-threatening conditions. Several parameters affect the 
severity the individual patient will experience; dosage, combination with 
other drugs/chemotherapy, the location of the tumor/s, the specificity of the 
drug and the state and medical history of the patient [174]. However, so far 
the exact parametric combination leading to a specific patient response 
does not exist.  
 
Anti-VEGF/VEGFR antibodies are mostly correlated with clotting disorders, 
resulting in wound complications, thrombosis or hemorrhage. Added to the 
list are also, hypertension, proteinuria (or worse), bowel perforation and 
reversible posterior leukoencephalopathy syndrome, to name a few more. 
RTK inhibitors present somewhat different adverse effects, due to the fact 
that they also target other molecules, not directly in the VEGF-pathway 
[174]. These effects are in part explained by the great variety of functions 
that are conducted by VEGF, which are thrown off balance upon anti-
VEGF treatment [175].  
 
The adverse effect above are acute, short-term effects. As Cook et al. state 
in their review of anti-angiogenic drugs, the long-term effects of these 
therapies are not yet fully known, since most drugs are so new on the 
market. [149]. 
 
 
5.4 Resistance 
 
Eventhough anti-angiogenic drugs have been beneficial for patients, the 
positive effect on cancer is mostly transient. During the course of 
treatment, or even before, patients stop responding to therapy. They have 
become resistant to the treatment. G. Bergers and D. Hanahan divide 
tumor resistance mechanisms to anti-VEGF drugs into two compartments: 
Adaptive (evasive) and intrinsic (pre-existing) non-responsiveness [176]. As 
a result of the VEGF blockade of the drugs, the evasive non-responsiveness 
starts with the upregulation of alternative signaling pathways. Bone 
marrow-derived pro-angiogenic cells are recruited to the tumor site in 
order to continue vascular remodelling and to further increase the VEGF-
independence pericyte coverage is increased. This mediated endothelial 
cell survival in the absence of VEGF. Lastly, the evasive responsiveness is 
characterized by the enhancement of tissue invasion and metastasis, a 
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means for the starved tumor cell to find a better vascularlized milieu in 
which to grow.  
 
The intrinsic (pre-existing) non-responsive tumors/tumor vessels already 
exhibit some of the traits mentioned above prior to anti-angiogenic 
treatment. This is thought to be caused by the selective pressure for that 
specific tumor. Tumors utilizing vessel co-option also fall into this 
category, as they do not rely upon neovascularization. This phenomenon 
explains why some patients do not respond to the treatment at all.  
 
The major drawback with anti-angiogenic therapy has not been so much 
the drug resistance per se, which occurs with other treatments as well, but 
the change in tumor aggressiveness [177]. In responding patients, this is 
explained by defense mechanisms triggered by oxygen deprivation, i.e. the 
last evading resistance mechanism described above. As a result, a more 
aggressive tumor type is selected and the patients end up with a rapidly 
progressing disease.  
 
By targeting multiple pathways, resistance may be overcome or delayed. 
This makes combining therapies an important notion also for anti-
angiogenic therapies. I hope that even more targeted therapy will help 
abolish the worst adverse effects and help in plugging the holes through 
which tumors continue to escape death.   
 
 
6 Anti-Angiomotin therapy 
 
Considering the development seen with anti-VEGF therapy, mentioned in the 
above section, the continued work on targeted drugs and analogs of endogenous 
inhibitors is most important. Taking all the data presented on Amot so far, I hope 
that the clinical potential of an anti-Amot treatment has become clear. And, 
considering the notion that an anti-Amot molecule is mimicking the effect of 
Angiostatin, I deem that the concept of anti-Amot therapy needs no further 
presentation. I this section, I present the collected findings of the Holmgren group 
and collaborators on anti-Angiomotin antibodies, to give a coherent image of the 
work done and what stands to be done on this matter. 
 
 
6.1 Patient generated antibodies – DNA Vaccination 
 
Some of the problems with endogenous inhibitors such as angiostatin are 
short circulatory half-life and expensive production. To circumvent this 
problem, a DNA vaccination approach was attempted. The rationale 
behind the project was that the vaccination would result in the patients 
themselves producing the anti-Angiomotin antibodies that would inhibit 
the pathological angiogenesis and thus halt tumor growth.  
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As always, the “patients” initially had to be mice, in this instance BALB-
NeuT mice. Holmgren et al 2006 show that a co-vaccination against 
human Angiomotin and the extracellular and transmembrane domains of 
Human Epidermal Growth Factor Receptor 2 (Her-2) prevents tumor 
(TUBO) formation for more than 70 weeks in 80% of the mice [88]. 
Vaccination against Angiomotin inhibited angiogensis, as shown through 
the lack of blood vessel ingrowth in the matrigel plug assay 
(microtumor/bFGF-induced angiogenesis) and delayed the onset of disease 
[84, 88]. The latter finding is remarkable, considering that vaccination 
against Neu did not elicit as efficient protection [84]. High, specific anti-
Amot antibody titers were received in both BALB-NeuT and –PyMT mouse 
models, indicating a good immune response and that the effects seen most 
probably are due to anti-Amot antibodies. Interestingly, vaccination against 
Amot resulted in an otherwise ineffective single dose of doxorubicin to 
take effect and either delay tumor growth or lead to tumor rejection [84].  
 
This shows a great potential for using anti-Angiomotin antibodies for 
treating highly vascularized tumors. Today, projects are still ongoing trying 
to modulate this vaccination (intra-muscular injection of plasmids followed 
by electroporation) approach into even better results, hopefully good 
enough to argue for clinical trials.  
 
 
 
6.2 The B06 antibody 
 
In collaboration with the pharmaceutical company BioInvent International 
(Lund, Sweden) a therapeutic anti-Amot antibody has been developed, 
intended for clinical use. The BioInvent way of antibody development is to 
use phage-display to screen the target protein (in this case Amot) against a 
single chain antibody fragment (scFv, see Figure 20) library called n-
CoDeR® [178]. The selected candidates are tested for affinity and 
biological function. The best candidate is then produced at large scale in 
eukaryote cells and the scFv fragment is coupled to a human IgG 
backbone, a so-called humanized antibody.  
 
In the case of the anti-Amot scFv, Boyden chamber migration assay was 
used in vitro and the matrigel plug assay in vivo to test functionality [97]. In 
the following section, multiple antibody formats will be presented, as 
illustrated by Figure 20.  
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Figure 20. Antibody formats. From Carter. 2006. Nature Reviews Immunology.  
 
6.2.1 The Single Chain Format 
 
The single-chain variable fragment (scFv) is an antibody fragment of 
approximately 30kDa consisting of the variable heavy and light chain 
domain joined by an amino acid linker. As a result of their monovalency 
and small size, scFvs clear quickly from the bloodstream via kidney 
excretion and have a half-life of 0.5 - 2 hours [179].  
 
The B06 scFv was functional for Fluorescent Activated Cell Sorting (FACS) 
analysis to verify Amot expression in cells and was able to stain blood 
vessel in sections from matrigel plus (bFGF-induced angiogenesis). 
Treatment of cells with the antibody resulted in inhibited endothelial cell 
migration and tube formation in vitro. This coincided with almost complete 
inhibition of angiogenesis in matrigel plugs in vivo and with the inhibition 
of retinal angiogenesis in neonatal mouse pups [97].  
 
However, with the low biological half-life, the scFv format of the B06 
antibody is not eligible for clinical trials as a therapeutic antibody. In 
upcoming sections this antibody has been put to other use.   
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6.2.2 The IgG-Format 
 
This version of B06 is a full antibody, IgG. It is composed of two synthetic 
scFv, coupled a human IgG backbone. The molecular weight of an IgG of 
approximately 150 kDa results in long residence in circulation for up to 3 
weeks [180]. This makes the IgG format suitable for therapeutic purposes 
as it results in longer intervals between doses. This is the format BioInvent 
works with and wished to develop.  
 
However, the work and results on the IgG format are mostly unpublished 
and the rights owned by BioInvent, so I will continue to describe other 
formats.  
 
 
6.2.3 The PEGylated F’Ab 
 
In the context of drug development, one way of circumventing the problem 
of short biological half-life is to conjugate the drug with polyethylene 
glycol (PEG) polymer chains. This process, called PEGylation renders the 
protein/drug larger, thus increasing the half-life, increasing water solubility 
and masking/ reducing immunogenicity of the drug in question [181]. This 
was done the F’ab format of the B06 antibody with a 20kDa PEG-maleimid 
compound and resulted in a reduction in the number of matrigel plug-
invading vessels (i.p. injection) (Figure 21) [97].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, despite the fact that PEGylation is generally accepted in the 
pharma industry the technology for efficient production has not yet been 
developed. Consequently, PEGylation is costly therefore commercially 
unattractive.  
  
Figure 21. The effect of i.p. injected, PEGylated B06 F'ab antibody into TUBO-stimulated matrigel 
plugs (panel H), compared to control F’ab antibody (panel G). From Levchenko et al. 2008. FASEB J.  
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6.2.4 The Imager 
 
Having a molecule with high specificity and affinity for its target, but a 
short half-life is not bad. For applications like immuno-in vivo imaging this 
is a desired characteristic. When it comes to immuno-positron emission 
tomography (immuno-PET), a short half-life means minimizing the time the 
substance resides within the patient and as a result reduces the radiation 
experienced by the patient and also the people in his/her close proximity. 
Also, long biological half-life brings with it logistical dilemmas for both 
caretakers and patients, since additional appointments may be needed (one 
for injection of tracer, one for imaging). As mentioned previously a full 
antibody (~150kDa) may remain up to 3 weeks in circulation, while the 
ScFv (~25kDa) clears quickly from the bloodstream in a matter of hours.  
 
Biomolecules such as proteins, e.g. antibodies, are ideal for targeted 
imaging. However, this technique is not widely used in the clinic due to 
the lack of efficient labeling procedures. Before injection, the biomolecule 
needs to be radio-isotope labeled, i.e. a radionuclide needs to be 
incorporated in the protein’s chemical composition. This can be 
accomplished by producing the protein in media containing radiolabeled 
amino acid, by inducing the exchange of normal for radiolabeled molecule 
using an enzymatic reaction or by changing the nucleophilic properties of 
antibody amino acid residues, making them susceptible to uptake of the 
radionuclide [182]. The group of E. Arnér has developed a method of 
efficient, residue-selective labeling and subsequent re-purification of 
proteins by using a so-called selenocystein (Sec) tag (Sel-tag) [183, 184]. In 
collaboration with Dr. Arnér a Sel-tag was added to the C-terminal of the 
B06 ScFv and the protein was labeled with carbon 11 (11C). As a tracer, 11C 
is used in the context of 11C-choline or 11C-methionine for PET-imaging 
[185]. It has a half-life of 20.38 min and gives rise to beta-irradiation 
during its decay [186]. Together with Dr. Sharon Stone-Elander the 11C -
B06 ScFv was injected into both healthy and tumor bearing mice.  
 
Figure 22 shows the kinetics and biodistribution of the B06 ScFv during 
60min of imaging in the PET-camera. Initially, the antibody goes to all 
major organs and later concentrates at the kidneys, for excretion, and at 
the tumor site. Figure 23 shows a PET-image of the antibody (tracer) uptake 
and shows the antibody targeting the tumor (MAE), comparing it to the 
current standard tracer for tumor sugar metabolism, the glucose analogue 
Fluoro-2-deoxy-D-glucose (FDG).  
 
These results are most interesting, but no study is complete without a 
negative control. Studies have shown that at early time-points after 
injection, small molecules and proteins are readily infiltrating the tumor 
from the vasculature, independent of specific binding [187]. Upon running 
Sel-tagged GFP we confirm that this is indeed the case. The GFP also 
localizes to the mouse tumors, similarly to the B06 ScFv, during this time  
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frame. According to literature the phenomenon of unspecific tumor 
localization time-limited [187]. There is a steady efflux of the non-binding 
protein from the tumor to the vasculature and later to the kidneys for 
excretion. This means that, given enough time the non-binding protein will 
be cleared. In contrast a protein specifically targeting an epitope within the 
tumor will reside much longer than the non-binder. Consequently, the 
distribution of the antibody and control should be compared at a later 
time-point. As shown in Tijink et al 2009 waiting up to 48h post-injection 
of the tracer yielded images with good background to signal ratios [188]. 
“A candle in the dark”, the signal quality to aim for in order to be able to 
use this technique for clinical practice.  
 
 
 
 
 
 
 
 
 
 
Figure 22. Kinetics analysis of 11C-labeled B06 ScFv in a tumor-bearing 
mouse. Unpublished data. 
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Potential anti-angiogenic drugs struggle in early clinical trials, since their 
effect is hard to measure [189]. The hope and aim for this version of the 
B06 antibody is to be able to determine whether or not the patient is 
responding to therapy by looking at blood vessel density by PET-imaging. 
By having a fast read-out this would help other drugs to reach the market 
and to further individualize therapy. 
 
In the future, I hope the use of more stable radio-isotopes with longer half-
life i.e. 124I will decide the fait of the B06 scFv as an immune-PET tracer 
and a potential diagnostic tool.  
 
 
6.2.5 The Diabody 
 
In the spectra of alterative antibody formats we also have the multivalent 
variants of the scFv: Dimeric (diabody), trimeric (Triabody) and tetrameric 
Figure 23. PET-image showing 11C-B06 scFv injected into tumor-bearing mouse. (A) Coronal section of whole 
mouse at 5-10 post injection. Head up. Tumor indicated by arrow. (B)  Transverse section of tumor. Left: 11C-B06 
scFv. Right: 18F-FDG. (C) Sectioned tumor, stained for B06 scFv, showing the vascular targeting of the antibody.   
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(Tetrabody). In the quest of increasing biological half-life without 
increasing the size to the extent of loosing biological activity, we chose to 
produce the B06 antibody as a diabody. As the name implies, a diabody is 
a dimer of two scFvs. Not only does this give rise to a larger molecular 
mass (~55kDa) and longer biological half-life (3-7 hours), it also opens up 
for the possibility of have a bispecific antibody [190]. Two scFv with 
different ligands. In the case of the B06 antibody, we chose to have a 
homodimeric diabody. Also, diabodies have been shown to have up to 40-
fold lower dissociation constants, giving them a much higher affinity to 
their target [191, 192].  
 
Diabodies can form spontaneously, depending on the characteristics of the 
scFv. However, the linker-region between the heavy and light chain of the 
scFv can be modified to induce non-covalent multimer formation. The B06 
scFv readily formed multimers over time, as the purified protein was stored. 
In order to force controlled dimerisation only, we therefore re-cloned and 
modified the linker region to 5 amino acids only. This renders the scFv 
unable to fold properly and allow the VL domain to bind the VH domain.  
In order to get Vl:Vh binding, the short linker scFv dimerizes. Triabodies 
and tetrabodies can be forced to form in the same fashion; by reducing the 
linker region size to less than three amino acid residues [193, 194].   
 
By dimerizing the B06 scFv antibody we hope to increase the half-life up 
to 7 hours. This format is the one to be used as a means of transporting 
toxic substances into the tumor and tumor vasculature, a technique called 
vascular targeting.   
 
 
6.2.6 The Trojan Horse/Vascular Targeting 
 
The Trojan horse was the means for the Greeks to, after a 10-year siege, 
enter Troy and end the war. They created a wooden horse, in which they 
hid a host of soldiers. Afterwards they sailed away, pretending to forfeit. As 
a trophy to their victory, the Trojans pulled the horse, and soldiers, inside 
the barricades and consequently lost the war. We hope to “build” our own 
Trojan horse in the shape of the B06 diabody, to gain access to the tumor 
tissue and angiogenic vessels. Instead of soldiers inside, we aim to couple 
it to toxic substances and kill off the angiogenic vessels and tumor cells, 
thus coming a ways to winning the war, and siege, of cancer.  
 
Vascular targeting is not a new concept and several potential drugs are 
undergoing clinical trials. However, choosing the most suitable agent for 
killing off angiogenic vessels at minimal risk for healthy tissue (in this case, 
especially kidneys) will take careful planning.  
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6.2.7 The Albumin Binding Domain 
 
The concept of an Albumin binding domain (ABD) to prolonge half-life is 
not new [195, 196]. The rationale is that the ABD is incorporated into the 
DNA and amino acid sequence of an antibody, or smaller antibody 
fragment. Upon injection into a blood stream, the ABD will bind to serum 
albumin and thus increase dramatically in size and be protected from 
kidney excretion. The bond between the ABD and serum albumin is non-
covalent and has a low affinity compared to the affinity of the antibody to 
its ligand. At any given time within the body, a certain amount of albumin-
bound and unbound antibody will exist. The albumin-unbound antibody 
will readily bind to its ligand and the bound may exchange the albumin for 
the ligand instead. 
 
We have coupled the B06 scFv to an ABD N-terminally and produced it in 
bacteria in small, medium and larger quantities. We are currently testing 
the different bonds; ABD-antibody:ligand, albumin:ABD-antibody and 
albumin:ABD-antibody:ligand to know if the functionality of the B06 scFv 
is compromised by the binding to albumin. Experiments in the nearby 
future will determine weather or not the ABD is truly prolonging serum-
half life in mice. 
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7 This Thesis 
 
Insufficient or exaggerated angiogenesis is a trait found in many diseases common 
in man. Looking beyond cancer, angiogenesis is affected in obesity, retinopathies, 
macular degeneration, hair loss, psoriasis, arthritis, endometriosis, Alzheimer’s 
disease, multiple sclerosis, stroke, erectile dysfunction and many more. Current 
anti-angiogenic therapies have been successful in treating some of these ailments. 
However, in the context of cancer the current therapies have mixed results. As 
patients become resistant they relapse and develop an even more aggressive 
disease. As mentioned in earlier paragraphs most current drugs are broad, targeting 
families of receptors involved in many other cellular functions and existing on 
more cells than endothelial cells.  
 
The aim of this thesis is to contribute to the understanding of angiogenesis by 
studying the function of Angiomotin. In parallel, drug development has been on the 
agenda, further developing a potential anti-Angiomotin drug for both therapeutic 
and diagnostic purposes. Surrounding mechanistic work has been paramount in 
trying to find other potential drug targets in the same functional pathway. All in all, 
this thesis aimed to find a new, specific angle from which to strike pathological 
blood vessels in the hope of aiding patients and further individualizing their 
therapy.  
 
7.1 Results and Discussion 
 
Paper I. The importance of the PDZ-binding motif in connecting 
Angiomotin to polarity proteins and affecting cell migration. 
 
We have previously shown that cells expressing a C-terminal Amot mutant 
lacking the last three amino acids, the PDZ-binding motif, exhibit 
migratory defects [57]. In this paper we wanted to identify the proteins 
binding to the PDZ-binding motif of Angiomotin and what their functions 
are in terms of regulating cellular migration.  
 
All members of the Motin family of proteins contains PDZ-binding motifs, 
hence Amot, AmotL1 and AmotL2 underwent the peptide pull-down 
experiments identifying their binding PDZ-binding domain partners. We 
show that all members bind to polarity and TJ proteins, indicating similar 
functions for all family members. We show that Angiomotin binds to the 
multi-PDZ domain containing protein Patj and Mupp1 and associates to 
their associated protein complex of Pals1 and Lin-7. This data was 
supported by two papers published while this article was under 
development [87, 90]. 
 
We also found a connection between Angiomotin and a protein called 
Syx1. The connection between Amot and Syx1 is thought to be indirect, as 
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both proteins have PDZ-binding domains but no PDZ-domains [95, 123]. 
Another protein is most likely modulating the connection between the two. 
Further assays identified Mupp1/Patj as a partner to Syx1, also in the 
context of the Pals1:Lin-7 complex.  
 
Syx1 is a RhoGEF, a protein exchanging GDP-RhoA for active GTP-RhoA. 
In this paper we perform a FRET-analysis using a RhoA-probe, showing 
localization of active RhoA in a cell. In the presence of Angiomotin, RhoA-
activity was concentrated to the leading edge of a migrating cell, similar to 
the localization of Amot. However, upon loss of angiomotin expression 
RhoA-activity was dispersed throughout the cell edges, resulting in the 
extensive protrusion activity, published earlier [61]. 
 
These data indicate that Angiomotin localizes RhoA-activity and 
concomitant actin polymerization at the right place and time during 
cellular migration. We therefore conclude that upon migratory stimuli, 
Angiomotin is localized to the leading edge of a cell, associating to polarity 
proteins and recruiting the RhoGEF Syx1, thereby localizing and 
concentrating RhoA activity at the leading edge. This is accomplished by 
the interaction of Angiomotin with the polarity complex 
Patj/Mupp1:Pals1:Lin-7, where both Angiomotin and Syx1 bind to 
Patj/Mupp1. Supporting out theory that Syx1 is indeed a protein acting 
downstream of Amot in the same signaling pathway is the data showing 
that Morpholino knock-down of syx1 mRNA expression phenocopies the 
loss of angiomotin mRNA expression.  
 
Conclusions from Paper I: 
• The Amot PDZ-binding domain is crucial for binding to polarity 
proteins and the Rho-GEF Syx1. 
• The miss-localization of the Rho-GEF Syx1 may explain the 
migratory dysfunction seen upon loss of Amot expression.  
• Morpholino knock-down (MO) of syx1 mRNA expression in 
zebrafish phenocopies that of MO of amot; impaired migration of 
intersegmental vessels.  
 
 
Paper II. The coiled-coil domain of Angiomotin binds to Merlin and 
Rich1, further connecting Angiomotin to the Rho-family of proteins and 
tumor development. 
 
In this paper the association between Angiomotin and Merlin was studied. 
We found that pull-down of Merlin resulted in the capture of Amot, 
AmotL1, Patj and Pals1. Further analysis show that Merlin does not interact 
with Patj nor Mupp1, but does interact directly with Amot (both isoforms) 
through their mutual coiled-coil domains.  
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Both Angiomotin and Merlin have been reported to localize to AJs and TJs. 
Calcium switch studies show that Angiomotin localizes to junctions several 
hours after the switch back to high calcium containing medium whereas 
Merlin localizes to primordial junctional structures already after 15 min. 
Further findings suggest that neither protein is dependent upon the other 
for its initial junctional localization. However, mutated and miss-localized 
Angiomotin dissociated Merlin from the TJs. This indicates that eventhough 
Angiomotin is not involved for the initial junctional localization of Merlin, 
it mediates the retention of Merlin at mature TJs.  
 
Angiomotin has been reported to interact with Syx1 and Rich1 (also known 
as ARHGAP17 or Nadrin), modulators of three members of the Rho-family 
of proteins: RhoA [65], Rac1 [61] and cdc42 [87]. 
 
Wells et al show that Angiomotin negatively regulates the GAP-activity of 
Rich 1 and consistent with that data we show that loss of angiomotin 
mRNA expression reduces the amount of active Rac1. In contrast, Merlin 
has been reported as a negative regulator of Rac1 and affecting the Ras-
MAPK pathway.  
 
ShRNA knock-down of angiomotin mRNA expression led to a decrease in 
the phosphorylation of several MAPK pathway activated molecules; c-Raf 
(S338), MEK (S298), ERK (T202/204), p95RSK (S380) and BAD (S112). 
However, phosphorylation of BAD (S136), a result of PI3K-AKT pathway 
signaling, was unaffected. Taken together these data show that Angiomotin 
regulates Rac1-Pak-MAPK signaling in an opposite manner from Merlin 
and Rich1.  
 
Our data suggests that both Angiomotin and Merlin require Rich1 to affect 
the MAPK-pathway. After further investigation we found that Rich1 was 
dissociated from Angiomotin by introduction of Merlin in a dose-
dependent manner. This indicates that Merlin and Rich1 may compete for 
the same binding site on Angiomotin and that the affinity for Merlin to 
Angiomotin is higher. This hypothesis was deemed plausible considering 
the finding by Wells et al. in 2006, where they found that Angiomotin and 
Rich1 interact through their mutual coiled-coil domains, similar to that of 
Angiomotin and Merlin. The exact cue from the extracellular environment 
and subsequent molecular mechanisms controlling this switch remain to 
be elucidated.  
 
Patients with mutations in the nf2 gene develop primarily Schwann cell 
tumors of peripheral nerves. In mice we show that the loss of nf2 
expression in Schwann cells in combination with a downregulation of 
amot mRNA expression leads to marked decrease in tumor growth rate and 
a prolonged mouse survival. This shows that Angiomotin is required for 
Schwannoma development due to loss of Nf2. It also emphasizes the 
potential for Angiomotin to be used as a drug target.   
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Conclusions from Paper II: 
§ Merlin and Angiomotin interact directly through their mutual 
coiled-coil domains.  
§ Merlin and Rich1 compete for binding sites on Angiomotin. 
During mitogenic signaling, Angiomotin binds to and sequesters 
Rich1, leading to an increase in Rac1 activity. During growth 
suppressive conditions Merlin binds to Angiomotin and Rich1 is 
free to inhibit Rac1 signaling through Ras-MAPK mitogenic 
pathways.  
§ Angiomotin expression is required for schwannoma development 
in nf2-deficient Schwann cells. 
 
 
Paper III. Identification of genes affected by the loss of angiomotin 
expression.  
 
We have previously reported that more than 75% of all amot negative 
mice die in utero at E11. Analysis of embryos at E9-11 showed severe 
vascular defects such as insufficient vascularization of the intersomitic 
region as well as dilation of cranial vessels [61].  
 
In this paper we study the surviving few mice but initially fail to find any 
apparent abnormalities. Upon studying organ vascularization standard 
histology examination and specific blood vessel staining reveal no 
detectable difference between wt littermates and amot negative mice. 
However, upon tumor xenograft implantation of Lewis Lung Carcinoma 
cells, the mice responded differently.  
 
We observe paler tumors in the amot negative mice and after inspection of 
tumor sections under microscope we conclude that this is caused by a 
marked reduction in vascularity. Perfusion studies revealed that not only 
did the amot negative mice exhibit fewer tumor blood vessels; the vessels 
present were poorly perfused.  
 
We show that even though these mice found a means to circumvent the 
effects of absent angiomotin expression during embryonic development, 
they were unsuccessful during pathological conditions. This supports the 
theory that there is a difference between physiological and pathological 
angiogenesis and indicates that Angiomotin plays an important role in this 
process.  
 
Gene expression analysis using microarray revealed that the loss of 
angiomotin mRNA/gene expression leads to effects on genes important for 
cellular migration and inflammation. We observed an involvement of the 
NF-κB pathway and a marked increase in gene expression of inflammatory 
receptors such as Immuno Cell Adhesion Molecule (ICAM)-1 and P-
Selectin (SELP).  
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In parallel with our finding that loss of angiomotin expression e.g. leads to 
effects on (software classification) “Cellular Movement” and 
“Cardiovascular System Development” we also found effects on 
“Organismal Survival” and “Cell Cycle”. However, when looking closer 
upon the genes regulated no coupling to the Hippo Pathway could be 
found, which was unexpected. More time needs to be spent looking at 
these results to see which pathway may be affected in this context.  
 
The changes in expression were confirmed both on mRNA and protein 
level using quantitative Polymerase chain reaction (qPCR), Fluorescence 
Activated Cell Sorting (FACS) analysis and ImmunoFluorescence (IF) on 
cells treated similarly to the microarray batches. The increased ICAM-1 
expression was also confirmed on blood vessels in tumor tissue from amot 
negative mice.  
 
It has been shown that cytoskeletal disruption can trigger an NF‐κB 
pathway response [197-201]. Loss of Amot expression leads to a marked 
effect on cytoskeletal integrity. We suggest that these cytoskeletal 
alterations may trigger an NF-κB pathway response both in vitro and in 
vivo, leading to the upregulation of inflammatory receptors like ICAM-1.  
 
In summary, we have identified a set of angiomotin-regulated genes 
involved in angiogenesis. Further studies are necessary to understand more 
of the mechanisms associated to these genes. We show that angiomotin 
expression is one component driving pathological angiogenesis and 
appears to be involved in tumor vessels maturation and subsequent 
perfusion. The loss of angiomotin is associated with an NF-κB pathway 
involvement and an upregulation of inflammatory receptors. Future studies 
will reveal if a specific population of immune cell is recruited to the tumor. 
 
Conclusions from Paper III 
• Adult angiomotin negative mice experience reduced pathological 
angiogenesis, combined with a low vessel perfusion.   
• Loss of angiomotin is associated with an NF-κB response and an up-
regulation of inflammatory receptors such as ICAM-1 and P-Selectin 
both in vivo and in vitro.  
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7.2 My Conclusions & Future Perspectives 
 
I think a wider approach is needed to map the function of a given protein. For us, 
this means that we, at every experiment, analyze the localization and levels of each 
Motin and their corresponding binding partner. Given the homology between the 
Motins, the overlap in function and tissue expression, there is a chance that the 
levels of the one will affect the function of the other. I believe this is the only way 
to accumulate enough data about the Amot, AmotL1 and AmotL2 trio to draw 
larger conclusion as to how they affect endothelial cells and an organism as a 
whole.   
 
When it comes to Amot in the context of migration I hypothesize that migratory 
cues such as high VEGF concentration attract chemical sensors associated to lipid 
rafts. The rafts accumulate, attracting lipid-binding proteins like BAR-domain 
containing proteins like Amot. Amot follows the rafts, bringing with it proteins like 
Patj:Pals1 and Syx1. In parallel, p80-Amot expression is upregulated and p130-
Amot is sequestered from the TJs, thus weakening the junction. Functional TJs need 
the entire Crb3:Pals1:Patj complex and the removal of Patj:Pals1 causes TJ 
disruption. Crb3 is internalized to endosomes, disbanding the TJs completely. The 
localization of Amot at the leading edge brings with it double effects on the actin 
cytoskeleton, one being the localization of Rho activity via Syx1, the other being 
removing the inhibition of Rac1 by sequestering Rich1 either at the leading edge or 
in the vesicles now containing p130-Amot in the cytoplasm.  
 
They way I see it there are several points of interest to study in order to sort out and 
eliminate hypotheses like mine.  
 
 
I. The MAP kinase pathway and contractility. The association of Amot and Merlin 
or Rich1 and subsequent activation/inhibition of the MAP kinase (MAPK) pathway 
(Pak1/2-MEKK1-MEK1/2-ERK—TF—Gene expression) needs to be investigated 
further.  
 
If we believe that both the findings from Paper I and Wells et al 2006 are correct 
then we need to find out in which context the one and/or the other is true. Amot 
binds Syx1, localizing ROCK activity and subsequent actomyosin contraction. 
Amot also binds to Rich1 and while Rich1 is bound Rac is active, free to activate 
PAK. PAK phosphorylates and inactivates Myosin Light Chain Kinase (MLCK) and 
leads to a decrease in contractility. This scenario seems unlikely to me: both 
promoting and inhibiting contractility at the same time. However, PAK has been 
reported to directly phosphorylate Myosin Regulatory Light Chain (MRLC), thus 
promoting contractility. The immediate question I think of are: Is Amot associated 
to other proteins in TJs versus in lamellipodia? Which ones? What decides when 
Merlin/Rich1 binds to Amot? Is Merlin constitutively expressed in both senescent, 
dividing, migrating and stationary cells, or is the expression timed with a certain 
cellular response? Or, is the expression of Merlin constant but the protein occupied 
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elsewhere in the TJs, only free to bind Amot and release Rich1 at a certain time-
point of cellular life? 
The reason I write “if” we believe the in the findings is because it has also been 
shown that the PDZ-binding motif of Amot, which is not essential for the Rich1 
interaction, is essential for the migratory function of p80-Amot [57]. 
In cells expressing the PDZ-binding motif mutant form of p80-Amot, p80-Amot is 
misslocalized (cytoplasmic), which would result in subsequent misslocalization of 
both Rho and Rac induced migration [86]. This could indicate that the proper 
localization of p80-Amot is dependent upon the PDZ-binding motif, in turn 
implying that localization is dependent on Patj/Mupp1. However, since Syx1 is 
misslocalized this cannot be. It could be that binding to Amot causes a 
conformational change in Patj/Mupp1, enabling Syx1 binding, but it seems 
unlikely. It can be that a series of partners are needed in order for Rich1 to bind the 
coiled-coil domain and that those partners need the PDZ-binding motif. No matter 
what, this phenomena needs more investigation.  
 
II. IL-8. Related to point I is the topic of IL-8. Taking into consideration our findings 
in Paper III of the increased expression of inflammatory receptors and NF-κB 
response upon loss of angiomotin expression together with the MAPK pathway, IL-8 
emerges. Firstly, the MAPK pathway may trigger NF-κB signaling. Secondly, 
expression of IL-8 can be triggered through both the MAPK and NF-κB pathway 
[202]. Thirdly, endothelial cells express Il-8. In fact, they even have IL-8-filled 
vesicles, ready to disperse the content into the extracellular space upon the correct 
cue [203]. The effect of IL-8 on ECs is the increase of proliferation, cell survival and 
the stimulation of several angiogenic properties, like MMP secretion [204]. In the 
gene expression analysis of Paper III we find no direct evidence of this. However, 
not enough time has been spent analysis the data in the MAPK context to be 
certain. Taken together this may explain why we see an involvement of “Cell 
cycle”, “Cell survival” and “Organismal survival” as parallel results when analyzing 
the microarray data from amot negative endothelial cells. We need to answer 
questions like: Is there a difference in IL-8 production in amot negative cells/mice?  
 
III. Isoform specificity and kinetics. We also need to pinpoint when and where 
Amot is interacting with all of its published partners. As I mentioned in Section 3.2 
our lab has published that overexpression of p80-Amot redistributes the 
localization of p130-Amot from TJs to the cytoplasm, resulting in a migratory 
phenotype [86]. This raises the question of what function each isoform is 
performing, in the context of binding partners. At confluency in TJs, which Amot 
isoform is interacting with Merlin? With Patj? Where is each isoform localized at 
different stages of cell life/movement and what is it interacting with? Where do 
Plekhg5 and Rac1 fit in all of this? Where is Crb3 localized in migrating ECs? Where 
is p130-Amot localized at the same time? Where is Merlin localized in amot knock-
outs? How does Axl expression fit into all of this? 
 
IV. Lipid rafts and the lipid composition of a cell. Lipid rafts are distinct 
subdomains of the plasma membrane, islands containing high concentrations of 
cholesterol and glycosphingolipids. Apart from lipids they also contain a variety of 
proteins, especially those involved in cell signaling. The immunological synapse is 
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one example of their importance. The coiled-coil domain of Angiomotin is a BAR-
domain specifically binding to lipids. According to Heller et al 2009, this domain 
(called ACCH) preferentially binds cholesterol rich membranes, more specifically 
membranes enriched in phosphoinositide-3-phosphate (PI(3)P) and PI(4)P. Upon 
polarization and migration cellular membranes demonstrate a distinct lipid 
composition, e.g. review by Wang and Margolis (2007). The lamellipodia (to where 
Amot localizes upon migration) consists mainly of PI(4,5)P2. This is inconsistent 
with the published findings by Heller. However, considering that the studies were 
only conducted on artificially constructed vesicular structures some binding data 
may have been missed. The Amot BAR-domain may still bind to a specific 
composition of phosphoinositides during “physiological” conditions in the cell. 
What is the lipid composition of lamellipodia of migrating ECs? Does Amot coiled-
coil domain bind to this composition of lipids? If so, what is the relation of these 
rafts and Amot during different time-points in the cell? Does the one co-localize 
with the other? This may shed light upon how Amot is relocalized to the 
lamellipodia upon EC migration. If there is a connection between the two, these 
rafts may be targets for drug design. E.g. Glucocorticoids may alter lipid raft 
composition and change cell behavior [205]. Can we remove amot from 
lamellipodia by removing/blocking a certain protein? 
 
Secondly, I believe that the findings of Heller et al should be looked into in more 
detail. PI(3)P and PI(4)P are mostly substrates for other PIs but (especially in the 
case of PI(3)P) are part of early endosome (EE) membranes and the multivesicular 
body (MVB) compartment. This, together with our findings that especially AmotL2 
localizes to endosomal structures calls for further investigation. Are PI(3)/(4)P 
important for AmotL2 function? Since the EEs have been implied in receptor 
recycling and Angiostatin is internalized upon binding to its receptor: Is Amot, like 
Merlin, involved in receptor recycling? 
  
V. The mechanism of anti-Amot therapy. The work with the B06 anti-antibody is 
ongoing and I am exited to hear of the outcome. Apart from answering the 
questions raised in Section 6: “Will it work for imaging tumor vessels? Did we 
manage to prolong halftime and retain biological function?” there are still some that 
would be nice to answer. I failed to crystalize the Amot coiled-coil domain, with 
and without the antibody. It would have been at nice way of seeing if the antibody 
affects the coiled-coil domain structurally. One hypothesis of how the B06 
antibody (and most probably angiostatin) exerts its anti-Amot function is that it 
causes a conformational change, causing a blockade of other binding sites for other 
partners. Another hypothesis, now made more explainable due to the EEs and BAR-
domain mentioned earlier, is the one of internalization and sequestration. How 
does the B06 antibody inhibit Amot function? The answer to this question I believe 
will help us understand more of Angiomotin signaling and yield more drug targets, 
all in order to fight off cancer and angiogenesis-associated diseases.  
 
VI. Prevention. However much I would love for anti-angiogenic therapy to be the 
solution to the global health problem of cancer I cannot help to feel that one of the 
best solution to the problem is to not get cancer in the first place. Cancer 
prevention is therefore an important field of research, where I believe that we, as 
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angiogenic researchers, may contribute greatly. It has been shown that a lot of both 
women and men carry in situ tumors in breast and prostate without developing 
cancer [206]. In order to develop into lethal disease these dormant tumors need 
other stimuli. One such factor can be the deregulation of endogenous angiogenesis 
inhibitors, caused by genetic mutations, dietary factors or other environmental 
factors. Personally, I find the notion of being able to halt tumor development by 
changing my diet, very interesting. However, I will continue dreaming about 
helping those who already have caught this dreadful disease.  
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